var title_f30_35_31280="OR setup LAVH";
var content_f30_35_31280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Operating room setup for laparoscopic-assisted vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31280=[""].join("\n");
var outline_f30_35_31280=null;
var title_f30_35_31281="Counter force brace for epicondylitis";
var content_f30_35_31281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Counter force brace for epicondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial management of lateral epicondylitis often involves the use of a counter force brace. Such&nbsp;bracing may reduce tendon and muscle strain at the origin of the forearm extensor muscles, thereby relieving pain and improving function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aircast/ProCare Brand. Copyright &copy; 2008 DJO Incorporated. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31281=[""].join("\n");
var outline_f30_35_31281=null;
var title_f30_35_31282="Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)";
var content_f30_35_31282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/4/28738\">",
"         Patient information: Care after rape or sexual assault (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/44/22210\">",
"         Patient information: Starting treatment for HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/0/7170\">",
"         Patient information: Symptoms of HIV infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/60/1986\">",
"         Patient information: Testing for HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preventing-hiv-after-unprotected-sex-or-needle-sharing-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H97468115\">",
"      <span class=\"h1\">",
"       How do you catch HIV from someone who is infected?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can catch HIV from someone who is infected if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Share the same needle, for example to inject drugs",
"       </li>",
"       <li>",
"        Have anal, vaginal, or oral sex with them",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is not very likely that you would catch HIV just by getting blood or other body fluids on your skin. But if you get blood or other body fluids in your vagina, anus, or inside the tip of your penis, you could get infected. It is also possible to get infected if blood or fluids with HIV get into your eyes or mouth, but this is less risky.",
"     </p>",
"     <p>",
"      Body fluids that are most dangerous include blood and the fluids that come from the penis, vagina, and anus during sex. Other body fluids are less dangerous, as long as they aren&rsquo;t mixed with blood. This includes urine, saliva, sweat, or tears.",
"     </p>",
"     <p>",
"      Human bites are unusual, but HIV can be passed from 1 person to another if 1 of them is infected, and the bite breaks the skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97468122\">",
"      <span class=\"h1\">",
"       Can I lower my chances of getting HIV even after being exposed to the virus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In some cases, yes. There are treatments that can reduce your risk of getting HIV (called &ldquo;preventive medicines&rdquo;), but you must start them within 3 days of being exposed to the virus.",
"     </p>",
"     <p>",
"      If you think you have been exposed to HIV, see your doctor or nurse right away. But keep in mind that medicines to prevent HIV after exposure are not for people who risk getting exposed over and over again. In other words, if you commonly have unprotected sex or use dirty needles, these treatments are not for you. Preventive medicines will not work in someone who always has risky behaviors. On the other hand, if an unusual event happened, like a condom broke, or you had unprotected sex, or you were raped, the medicines might help you.",
"     </p>",
"     <p>",
"      You should also keep in mind that the risk of getting HIV after 1 exposure is usually pretty low. Still, it is always best to discuss your risk of HIV with your doctor or nurse. He or she can give you the best advice after an exposure. Don&rsquo;t try to figure out your risk of HIV on your own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97468129\">",
"      <span class=\"h1\">",
"       How likely is it that I will catch HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on a lot of factors, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        How you were exposed &mdash; Some ways of getting exposed are riskier than others. For example, although it is possible to catch HIV through oral sex, it is unusual. On the other hand, sharing dirty needles is extremely risky. Also, anal sex is riskier than vaginal sex.",
"       </li>",
"       <li>",
"        Whether you have any sores or cuts on the part of your body that was exposed &mdash; People who have open wounds or sores are more likely to get infected. For example, if you have herpes sores on your genitals, your risk of catching HIV goes up.",
"       </li>",
"       <li>",
"        Whether the body fluids you were exposed to came from a person who actually has HIV &mdash; If the person has HIV but is being treated, your risk will be low. If the person has HIV and has a lot of virus in his or her blood, your risk of getting HIV goes up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97468136\">",
"      <span class=\"h1\">",
"       What will the doctor or nurse do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, your doctor or nurse will probably test you for HIV. This will tell him or her whether you were already infected with the virus in the past. If so, it won't make sense to give you medicine to prevent HIV infection. Then your doctor or nurse will talk to you about the chances that you could get infected, and what you can do about it. You and your doctor will have to decide if HIV medicines are right for you based on how likely it is that you could become infected, and on how you feel about the risks and benefits of taking medicines.",
"     </p>",
"     <p>",
"      If the 2 of you decide that you should take medicines to prevent HIV infection, your doctor or nurse might prescribe 2 or 3 different medicines. You will need to start these as soon as possible and take them for a month.",
"     </p>",
"     <p>",
"      If the person who exposed you is willing to be tested, your doctor or nurse might test him or her also. If the person who exposed you doesn&rsquo;t have HIV, then you won&rsquo;t have to take HIV medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97468143\">",
"      <span class=\"h1\">",
"       What are the risks or side effects of medicines to prevent HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The side effects differ depending on which specific medicines you take. Ask your doctor which side effects to expect and what to do about them.",
"     </p>",
"     <p>",
"      If you are pregnant or could be pregnant, tell your doctor or nurse. Some medicines are not safe to use in pregnant women, so your doctor or nurse needs to know if you are or could be pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97468150\">",
"      <span class=\"h1\">",
"       What happens after I am done taking the medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will test you again to see if you got infected with HIV. These tests will be done at 6 weeks, 3 months, and 6 months after your exposure. Your doctor might also test you for other types of infections you can catch through sex. If you are a woman, your doctor will check to make sure you did not get pregnant.",
"     </p>",
"     <p>",
"      It is very important that you take all the medicine your doctor prescribes. Still, even if you take all your medicine as directed, there is no guarantee that you will not get infected. The medicines improve your chances, but they do not always prevent infection. That is why it is best not to share needles or have unprotected sex in the first place.",
"     </p>",
"     <p>",
"      In the weeks after your exposure, look for symptoms of HIV infection, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Swollen glands",
"       </li>",
"       <li>",
"        Sore throat",
"       </li>",
"       <li>",
"        Sores in your mouth, penis, anus, or vagina",
"       </li>",
"       <li>",
"        Muscle and joint pain",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you notice any symptoms that worry you, call your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97468157\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Until you know for sure whether you have HIV, make sure to use condoms during sex. Or avoid sex. Do not donate blood, sperm, or any tissues. Otherwise, if it turns out you did catch HIV, you could infect someone else.",
"     </p>",
"     <p>",
"      You might also want to check whether you got any other infections besides HIV. People with HIV often have other infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97468270\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=see_link\">",
"       Patient information: Starting treatment for HIV (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/4/28738?source=see_link\">",
"       Patient information: Care after rape or sexual assault (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/60/1986?source=see_link\">",
"       Patient information: Testing for HIV (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/0/7170?source=see_link\">",
"       Patient information: Symptoms of HIV infection (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/35/31282?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16274 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31282=[""].join("\n");
var outline_f30_35_31282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468115\">",
"      How do you catch HIV from someone who is infected?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468122\">",
"      Can I lower my chances of getting HIV even after being exposed to the virus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468129\">",
"      How likely is it that I will catch HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468136\">",
"      What will the doctor or nurse do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468143\">",
"      What are the risks or side effects of medicines to prevent HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468150\">",
"      What happens after I am done taking the medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468157\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97468270\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/4/28738?source=related_link\">",
"      Patient information: Care after rape or sexual assault (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/0/7170?source=related_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/60/1986?source=related_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_35_31283="Arteriogram in RA stenosis";
var content_f30_35_31283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71793%7ENEPH%2F67188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71793%7ENEPH%2F67188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortogram showing renal artery stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aortogram shows a focal stenosis of the left renal artery with poststenotic dilatation (arrow). The right renal artery has a normal caliber and is delivering contrast to the right kidney well before the left kidney recieves contrast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Percutaneous transluminal renal angioplasty for renal artery stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal arteriogram after percutaneous transluminal renal angioplasty (PTRA) has largely corrected the stenotic lesion in the right renal artery (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Rose BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31283=[""].join("\n");
var outline_f30_35_31283=null;
var title_f30_35_31284="MRI ependymoma";
var content_f30_35_31284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Magnetic resonanc image of an ependymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) A sagittal T1 image with contrast of an ependymoma that arises in the 4th ventricle causing obstruction and hydrocephalus. Panel B) An axial T1 image of the same lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Blaney.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31284=[""].join("\n");
var outline_f30_35_31284=null;
var title_f30_35_31285="Retained surgical sponge on magnetic resonance imaging";
var content_f30_35_31285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retained surgical sponge on magnetic resonance imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paravertebral gossypiboma in patient with lumbar pain, fever, and palpable mass. Patient had undergone prior laminectomy. Coronal T1-weighted image after IV injection of contrast material shows strong enhancement of peripheral rim (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Professor Giuseppe D'Ippolito. Originally published in: Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: pictorial review. AJR Am J Roentgenol 2009; 193:S94.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31285=[""].join("\n");
var outline_f30_35_31285=null;
var title_f30_35_31286="Choosing a modality for chronic peritoneal dialysis";
var content_f30_35_31286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Choosing a modality for chronic peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31286/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31286/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31286/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31286/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31286/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31286/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/35/31286/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different techniques are available for performing peritoneal dialysis (PD). Before discussing these modalities, it is helpful to briefly review the determinants of solute clearance with PD. The rates of peritoneal blood flow and dialysate flow with PD are well below those achieved with hemodialysis (where both are often above 400",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    Thus, the clearance of urea and other small solutes per unit time is much less with PD than with hemodialysis. However, PD is often performed in a continuous fashion so that the weekly solute clearances approach those with hemodialysis.",
"   </p>",
"   <p>",
"    It is also important to appreciate that urea rapidly diffuses into the peritoneal dialysate (which initially contains no urea) so that the average dialysate-to-plasma urea ratio is 0.70 at two hours and 0.90 at four hours. Comparable values for creatinine are 0.50 and 0.65, respectively (",
"    <a class=\"graphic graphic_figure graphicRef75224 \" href=\"mobipreview.htm?32/26/33198\">",
"     figure 1",
"    </a>",
"    ). Thus, urea and other small solutes are rapidly removed in the first few hours of a dwell; after four hours, there is very little further removal of small solutes due to near equilibration in concentrations. There is, however, continued removal of larger solutes, which do not equilibrate as rapidly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;PD can be performed in a continuous or intermittent fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/1\">",
"     1",
"    </a>",
"    ]. Continuous ambulatory peritoneal dialysis (CAPD) involves multiple exchanges during the day (usually three) followed by an overnight dwell. A modification involves one nighttime exchange with an exchange device, resulting in two overnight exchanges and three exchanges during the day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/2\">",
"     2",
"    </a>",
"    ]. There used to be a device designed specifically for this option (the nightly exchange device) however this device is no longer available. As a result, this modification of CAPD is seldom used; when it is used, a standard cycler is required.",
"   </p>",
"   <p>",
"    Automated peritoneal dialysis (APD) uses a cycler to perform multiple overnight exchanges. Modifications to this technique include continuous cycler peritoneal dialysis (CCPD), nightly intermittent peritoneal dialysis (NIPD), and tidal peritoneal dialysis (TPD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous cycler peritoneal dialysis (CCPD) has a long daytime dwell and several cycles overnight. A minority of patients undergoing CCPD do not have a daytime dwell and some patients must also do a midday exchange to meet adequacy or UF targets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some intermittent techniques, such as nightly intermittent peritoneal dialysis (NIPD) or intermittent peritoneal dialysis (IPD), have treatment periods (\"wet\" abdomen) alternating with times during which the peritoneal cavity has been drained of dialysate (\"dry\" abdomen).",
"     </li>",
"     <li>",
"      Tidal peritoneal dialysis (TPD), consists of exchanges in which the peritoneal cavity always contains at least some dialysate (usually at least one-half full), a feature that improves comfort and facilitates drainage in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/4\">",
"       4",
"      </a>",
"      ]. The patient may or may not have a daytime dwell.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intermittent regimens typically utilize multiple short dwells and automated technology to operate at near maximum solute clearance rates. Of the intermittent techniques, TPD is infrequently used because it is relatively expensive (requires a larger amount of dialysate) and is technically more difficult to perform. Increased solute clearances have also not been confirmed in all patients, despite such findings in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Most frequently, TPD is used to minimize drainage problems in selected patients. As recommended in the European Best Practice guidelines, it can also be used in those with",
"    <span class=\"nowrap\">",
"     inflow/outflow",
"    </span>",
"    pain and in patients with slow peritoneal drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous flow peritoneal dialysis (CFPD) is another technique in which two peritoneal catheters or one catheter with two ports provide the continuous inflow and outflow of dialysate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/7\">",
"     7",
"    </a>",
"    ]. Since the dialysate is constantly refreshed, clearances of some solutes similar to that obtained with short daily hemodialysis can be obtained. CFPD was first introduced decades ago, but was subsequently abandoned because of technical and financial limitations.",
"   </p>",
"   <p>",
"    There has been a renewed interest in this technique because of the increased recognition of frequently inadequate clearances with other PD modalities and the introduction of technical innovations that may make CFPD feasible. One crossover study of five patients found that CFPD enhanced diffusive transport and the mean ultrafiltration rate compared with nightly intermittent PD and nightly tidal PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/8\">",
"     8",
"    </a>",
"    ]. Additional study is required to better understand the practicality of this technique. However as of 2011, technologies for daily hemodialysis have been very successful and perhaps as a result, there is little interest in CFPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAPD VERSUS APD",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is whether there are unique clinical advantages among the different CAPD or APD modalities. Although there is a paucity of data, CAPD and APD appear to provide similar selected clinical outcomes including mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This was shown in a systematic review of three randomized controlled trials that consisted of 139 patients undergoing either APD or CAPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Both PD modalities resulted in similar mortality and hospitalization rates, risk of peritonitis, and fluid leaks. APD may be associated with relatively more time for work and social activities.",
"     </li>",
"     <li>",
"      In a prospective multicenter cohort five-year study of 87 APD and 562 CAPD patients, overall mortality and the incidence of technique failure were the same with both techniques [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative effect of CAPD and APD on residual renal function is controversial. A large observational study of 505 CAPD and 78 APD patients showed a higher risk of complete loss of renal function in the first year associated with APD compared to CAPD (adjusted hazard ratio 2.66 [95% CI, 1.60-4.44]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/13\">",
"     13",
"    </a>",
"    ]. However, no difference was detected in the systemic review cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Larger randomized trials are needed to definitively answer this question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIALYSIS PRESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;How to choose between the modalities will be reviewed below. At the start of dialysis when patients have some residual renal function, most patients could do any PD technique and usually be able to achieve the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and volume control targets. However, once residual kidney function is negligible, modality choice may need to match peritoneal transport characteristics to optimize solute clearance and ultrafiltration. It is helpful, however, to first discuss the factors that determine the dialysis prescription.",
"   </p>",
"   <p>",
"    At times, it will be important to individualize the patient's dwell times and dwell volumes so that the target dose of PD can be achieved. As an example, PD is considered adequate in most patients if the weekly total",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    for urea is at least 1.7 and, if considering creatinine clearance, the weekly creatinine clearance is at least 50 to 60",
"    <span class=\"nowrap\">",
"     L/week",
"    </span>",
"    per 1.73 m2 body surface area (with some variation based upon transporter status) (see next section). Attainment of these goals must be documented and then monitored over time. It is often necessary, for example, to increase the patient's dialysis prescription (usually by increasing the number of exchanges or the dwell",
"    <span class=\"nowrap\">",
"     volume/exchange)",
"    </span>",
"    as residual renal function is lost or there is a decrease in the peritoneal membrane transport characteristics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peritoneal equilibration test (PET)",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the start of dialysis, peritoneal membrane transport is not known. Once stable on PD, in order to optimize a PD prescription, a test to characterize PD membrane transport (such as a PET test) is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .) Based upon published norms, the patient's transport characteristics are classified (",
"    <a class=\"graphic graphic_figure graphicRef65815 \" href=\"mobipreview.htm?1/63/2047\">",
"     figure 2",
"    </a>",
"    ). The dwell time can then be matched to the transport type in an effort to maximize daily clearances and ultrafiltration while minimizing glucose absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/15\">",
"     15",
"    </a>",
"    ]. The PET test is usually performed after about one month on PD to minimize early effects PD fluids may have on membrane transport. However, during training the observed drain volume after a two hour dwell with 2.5 percent dextrose tends to be predictive of transport type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Rapid transporters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consider, for example, the problem in \"rapid\" transporters of creatinine from the blood to dialysate. These patients achieve almost total equilibration between plasma and dialysate for urea and creatinine in a few hours. They also are rapid absorbers of dialysate glucose, thereby removing the osmotic stimulus to ultrafiltration (",
"    <a class=\"graphic graphic_figure graphicRef65815 \" href=\"mobipreview.htm?1/63/2047\">",
"     figure 2",
"    </a>",
"    ). The net effect is that they often begin to absorb dialysate, after two to three hours, resulting in reductions in ultrafiltration volume and net solute clearance (as the solutes that have diffused into the dialysate are also absorbed back into the systemic circulation) (",
"    <a class=\"graphic graphic_figure graphicRef62604 \" href=\"mobipreview.htm?6/26/6574\">",
"     figure 3",
"    </a>",
"    ). In this setting, standard CAPD, which utilizes prolonged dwell times, might not produce sufficient fluid or solute removal. This would necessitate the more frequent use of hypertonic dialysate (2.5 or 4.25 percent dextrose), potentially inducing hyperglycemia, hypertriglyceridemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight gain from the increase in glucose absorption, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    . A better alternative in many cases is multiple short dwells with standard dialysate as with NIPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Slow transporters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings are different in \"slow\" transporters who need long dwell times to adequately remove small solutes. Ultrafiltration is not a problem in this setting, since glucose is also slowly absorbed. Figure 3, for example, shows the findings of a two liter dwell volume with a four hour dwell time using 2.5 percent dextrose dialysate (",
"    <a class=\"graphic graphic_figure graphicRef62604 \" href=\"mobipreview.htm?6/26/6574\">",
"     figure 3",
"    </a>",
"    ). A slow transporter will have an adequate drain volume of 2.7 liters, but only 1.2 liters of creatinine clearance. A rapid transporter, on the other hand, will have a higher solute clearance but may have a drain volume that is actually less than the instilled volume. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36215?source=see_link\">",
"     \"Rapid transporters on maintenance peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Residual renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically have some residual renal function when they are started on maintenance dialysis. In this setting, it may not be as important to match dwell time with transporter type, since the urine volume can replace the need for ultrafiltration and the minimal renal solute excretion augments that due to dialysis. However, as the residual renal function gradually decreases over time, matching of dwell time to transport type becomes increasingly important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHOICE OF PD MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients on maintenance PD need continuous dialysis with CAPD or CCPD to achieve adequate weekly solute clearances. CAPD can be used, with a typical minimum dialysis prescription of four, two liter exchanges per day, including one overnight exchange. This standard regimen can be modified by changing either dwell time,",
"    <span class=\"nowrap\">",
"     volume/exchange",
"    </span>",
"    or the number of exchanges per day. The exchanges are performed manually.",
"   </p>",
"   <p>",
"    In comparison, CCPD is an automated form of therapy in which a cycler delivers three to six exchanges while the patient sleeps with a 12 to 15 hour daytime dwell. Weekly clearances are similar to those obtained with CAPD but more dialysate fluid is generally required each day. Some evidence suggests that ultrafiltration rates may be lower with automated forms of therapy, unless one carefully modifies the prescription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/17\">",
"     17",
"    </a>",
"    ]. In our unit, over 75 percent of patients use CCPD, and we are able to achieve adequacy and ultrafiltration goals by individualizing their prescriptions.",
"   </p>",
"   <p>",
"    We usually let the patient choose between CAPD and CCPD based upon lifestyle or personal issues (such as the desire to work, wish to not do any exchanges during the day, or, in a patient who is not able to do the exchanges themselves). In a prospective randomized study, CCPD provided significantly more time for work, family, and social activities than CAPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/18\">",
"     18",
"    </a>",
"    ]. Sleep apnea may also be more responsive to nocturnal PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further recommendations are made after the dialysis dose has been documented with a 24 hour dialysate collection for volume and creatinine clearance or",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    or it is determined from the peritoneal equilibration test that a change in prescription is needed.",
"   </p>",
"   <p>",
"    The patient should also be monitored over time for the loss of residual renal function. The associated fall in solute clearance can usually be reversed by increasing the dialysis prescription via an increase in the dwell volume or the number of exchanges per day. Either of these modalities will raise the net dialysate flow rate, thereby enhancing the clearance of urea and other small solutes by maintaining a favorable concentration gradient for solute diffusion (",
"    <a class=\"graphic graphic_figure graphicRef66264 \" href=\"mobipreview.htm?7/63/8190\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, automated peritoneal dialysis is superior to CAPD in optimizing fluid and small solute removal in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/20\">",
"     20",
"    </a>",
"    ]. This is because automated techniques can combine larger dwell volumes, long nocturnal sessions, and add daytime exchanges, thereby moderately increasing solute and fluid removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Body surface area",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to transport type, residual renal function, and life style choice, another factor to consider when prescribing PD is body surface area because both",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and the weekly creatinine clearance must be normalized to body size. For example, an absolute creatinine clearance of 60",
"    <span class=\"nowrap\">",
"     L/week",
"    </span>",
"    represents different degrees of dialytic solute removal in small versus large patients.",
"   </p>",
"   <p>",
"    Large patients typically need high dialysate volumes, particularly if they are slow transporters and have no residual renal function. With CAPD, the dwell volume is typically 2.5 or 3 liters and some patients require five exchanges per day.",
"   </p>",
"   <p>",
"    Large, anuric patients who are on CCPD, will often need 12 to 14 hours of dwell time while on the cycler, using large instilled volumes of dialysate; an alternative is a shorter cycler time (9 to 11 hours) plus one or two daytime exchanges. A large instilled volume is also required during the daytime dwell and some patients need to perform one manual CAPD exchange to meet the goal for solute clearance. However, increasing the nightly dialysate flow may be superior to adding a manual daytime exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31286/abstract/21\">",
"     21",
"    </a>",
"    ]. One should remember that there are ways to disconnect from the cycler and then reconnect to do an exchange. With this &ldquo;break away or high dose CCPD&rdquo; mode, the patient includes the manual exchanges he or she will do making when they set up the cycler, so that time spent doing exchanges is shorter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intermittent PD (IPD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intermittent therapies has evolved as we have become better able to match dwell time and volume to transport characteristics. In general because of the presence of residual kidney function, many patients can start dialysis with a low dose of PD or on an intermittent therapy. However as residual kidney function declines, the prescription will likely need to increase. As an example, rapid transporters do best with",
"    <strong>",
"     short dwells",
"    </strong>",
"    and may initially achieve adequate dialysis clearances with a \"dry\" day option on APD. At the initiation of dialysis if one still had enough residual kidney function, one might only have to do IPD for a six to eight hour session three or four days a week. In this case patient could even get the treatment at a dialysis center until ready to train for PD or a permanent HD access can be placed.",
"   </p>",
"   <p>",
"    However, as residual kidney function decreases, the frequency of the IPD treatment will need to be increased, eventually becoming a daily routine (such as NIPD). If NIPD is used with 8 to 12 hours of overnight dialysis, the dwell time may be only one to two hours per exchange with 1.5 to 2.0 liter dwell volumes. This requires the use of 8 to 20 liters of dialysate fluid per day. Adequate solute clearances can be achieved with this regimen even though the patient has a \"dry\" day. However, unless residual renal function is significant, most patients need a \"wet\" day. Among patients who are rapid transporters, the solution used for the long dwell should be carefully selected in order to avoid lymphatic absorption; such patients may need to use an osmotic agent other than dextrose (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     Icodextrin",
"    </a>",
"    ) or will need to do a midday exchange.",
"   </p>",
"   <p>",
"    It is currently estimated that 10 to 15 percent of patients might do best with NIPD, or daytime ambulatory peritoneal dialysis (DAPD). DAPD is similar to NIPD except that the exchanges are performed manually during the day.",
"   </p>",
"   <p>",
"    Classic IPD is a form of dialysis in which multiple short exchanges are performed on an intermittent basis. A typical regimen consists of 12 to 15 two liter, one hour dwells performed three or four days per week. Over 50 hours of dialysis are required to attain clearances similar to CAPD. However, even higher target doses of dialysis are recommended because of the peaks in BUN occurring on the off-dialysis days. For these reasons, this form of PD is not recommended for chronic use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/43/16051?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287936763\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritoneal dialysis (PD) can be performed using several different techniques. Continuous ambulatory peritoneal dialysis (CAPD) involves multiple exchanges during the day (usually three) followed by an overnight dwell. Automated peritoneal dialysis (APD) refers to techniques that use an automated device to do multiple exchanges overnight with or without a daytime dwell such as continuous cycler peritoneal dialysis (CCPD), nightly intermittent peritoneal dialysis (NIPD), and tidal peritoneal dialysis (TPD). Of these, CCPD, the most commonly used, has a long daytime dwell and several cycles overnight. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of PD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upon initiating PD, we usually let the patient choose the modality (most commonly either CAPD or CCPD) based upon lifestyle or personal issues since the choice is unlikely to matter as far as achieving",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      and ultrafiltration goals. This is because most patients initially have significant residual renal function. Over time, the prescription has to be modified because of the loss of renal function. The principal factors that determine the optimal PD prescription are membrane transport type, degree of residual renal function, life style choice, and body surface area. In general, APD therapies are recommended for rapid transporters; low transporters who desire to continue with APD therapy will likely require a midday exchange to achieve adequate",
"      <span class=\"nowrap\">",
"       fluid/solute",
"      </span>",
"      removal. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dialysis prescription'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Choice of PD modality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/1\">",
"      Twardowski ZJ. Peritoneal dialysis glossary III. Perit Dial Int 1990; 10:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/2\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/3\">",
"      Dell'Aquila R, Rodighiero MP, Span&oacute; E, et al. Advances in the technology of automated, tidal, and continuous flow peritoneal dialysis. Perit Dial Int 2007; 27 Suppl 2:S130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/4\">",
"      Juergensen PH, Murphy AL, Pherson KA, et al. Tidal peritoneal dialysis to achieve comfort in chronic peritoneal dialysis patients. Adv Perit Dial 1999; 15:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/5\">",
"      Juergensen PH, Murphy AL, Pherson KA, et al. Tidal peritoneal dialysis: comparison of different tidal regimens and automated peritoneal dialysis. Kidney Int 2000; 57:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/6\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/7\">",
"      Diaz-Buxo JA. Evolution of continuous flow peritoneal dialysis and the current state of the art. Semin Dial 2001; 14:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/8\">",
"      Freida P, Issad B. Continuous flow peritoneal dialysis: assessment of fluid and solute removal in a high-flow model of \"fresh dialysate single pass\". Perit Dial Int 2003; 23:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/9\">",
"      Rabindranath KS, Adams J, Ali TZ, et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev 2007; :CD006515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/10\">",
"      Rabindranath KS, Adams J, Ali TZ, et al. Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2007; 22:2991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/11\">",
"      Michels WM, Verduijn M, Boeschoten EW, et al. Similar survival on automated peritoneal dialysis and continuous ambulatory peritoneal dialysis in a large prospective cohort. Clin J Am Soc Nephrol 2009; 4:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/12\">",
"      Mehrotra R, Chiu YW, Kalantar-Zadeh K, Vonesh E. The outcomes of continuous ambulatory and automated peritoneal dialysis are similar. Kidney Int 2009; 76:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/13\">",
"      Michels WM, Verduijn M, Grootendorst DC, et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6:537.",
"     </a>",
"    </li>",
"    <li>",
"     Twardowski, ZJ. PET&mdash;A simpler approach. In: Advances in Peritoneal Dialysis, vol. 7, Khanna, R, et al (Eds), Peritoneal Dialysis Bulletin, Nashville, 1990, pp. 186-191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/15\">",
"      Twardowski ZJ. Nightly peritoneal dialysis. Why, who, how, and when? ASAIO Trans 1990; 36:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/16\">",
"      Davies SJ, Phillips L, Griffiths AM, et al. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/17\">",
"      Rodriguez-Carmona A, P&eacute;rez-Font&aacute;n M, Garca-Naveiro R, et al. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/18\">",
"      Bro S, Bjorner JB, Tofte-Jensen P, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/19\">",
"      Tang SC, Lam B, Ku PP, et al. Alleviation of sleep apnea in patients with chronic renal failure by nocturnal cycler-assisted peritoneal dialysis compared with conventional continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2006; 17:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/20\">",
"      P&eacute;rez-Font&aacute;n M, Rodr&iacute;guez-Carmona A. Comparing CAPD and automated peritoneal dialysis: where do solute transport issues stand? Perit Dial Int 2007; 27:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31286/abstract/21\">",
"      Demetriou D, Habicht A, Schillinger M, et al. Adequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled trial. Kidney Int 2006; 70:1649.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1858 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31286=[""].join("\n");
var outline_f30_35_31286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H287936763\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF PD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAPD VERSUS APD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIALYSIS PRESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peritoneal equilibration test (PET)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Rapid transporters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Slow transporters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Residual renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHOICE OF PD MODALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Body surface area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intermittent PD (IPD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287936763\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1858|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/26/33198\" title=\"figure 1\">",
"      Solute removal in PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/63/2047\" title=\"figure 2\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/26/6574\" title=\"figure 3\">",
"      PET rapid vs slow transporters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/63/8190\" title=\"figure 4\">",
"      Dialysate flow and solute clearance in PD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36215?source=related_link\">",
"      Rapid transporters on maintenance peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_35_31287="Pathogenesis of myasthenia gravis";
var content_f30_35_31287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of myasthenia gravis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31287/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31287/contributors\">",
"     Walter Allan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31287/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31287/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31287/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31287/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/35/31287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles. Muscle weakness due to dysfunction of the neuromuscular junction (myasthenia) may be an acquired disorder. The vast majority of patients who develop myasthenia in adolescence or adulthood have autoantibodies that play a pathogenetically important role by attacking the acetylcholine receptor (AChR), fixing complement, and reducing the number of AChRs over time. These autoantibodies are thought to originate in hyperplastic germinal centers in the thymus where myoid cells expressing AChR are clustered. Such antibody-mediated disease is referred to as myasthenia gravis.",
"   </p>",
"   <p>",
"    Similar weakness can also result from mutation of components of the neuromuscular junction, resulting in a group of disorders collectively referred to as \"congenital myasthenia\". This type of myasthenia is often appreciated at birth. Congenital myasthenia and weakness in newborns that is due to transplacental passage of antibodies from a pregnant woman with myasthenia gravis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of myasthenia gravis is discussed in this topic review. Other aspects of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is a condition that fulfills all the major criteria for a disorder mediated by autoantibodies against the acetylcholine receptor (AChR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The autoantibodies are present in 80 to 90 percent of affected patients",
"     </li>",
"     <li>",
"      The autoantibodies react with a specific antigen, the acetylcholine receptor",
"     </li>",
"     <li>",
"      The condition can be passively transferred by the autoantibodies to an animal model, producing a similar clinical condition",
"     </li>",
"     <li>",
"      Repeated injection of the human antigen in other species produces a model disease",
"     </li>",
"     <li>",
"      Reduction in autoantibody levels is associated with clinical improvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several observations indicating that the AChR antibody is directly responsible for the clinical symptoms. As an example, a decrease in the number of active acetylcholine receptors has been demonstrated to occur as a consequence of AChR antibody binding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/3\">",
"     3",
"    </a>",
"    ]. This may be due to autoantibody binding alone early in the disorder, but destruction of receptors eventually occurs via a complement-mediated process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the linkage between AChR antibodies and myasthenia gravis is not absolute. The plasma concentration of AChR antibodies does not correlate well with the severity of the disease, although in individual patients, changing autoantibody levels can be used to monitor treatment efficacy. Furthermore, 10 to 20 percent of patients with myasthenia gravis have no detectable levels of autoantibodies against the AChR. A proportion of these patients (40 to 70 percent) have antibodies directed against the muscle-specific receptor tyrosine kinase (MuSK). Accumulating evidence suggests that autoantibodies directed against MuSK and perhaps other postsynaptic neuromuscular junction components have a pathogenic role in the development of myasthenia gravis. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'MuSK antibodies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'Double-seronegative myasthenia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acetylcholine receptor antibody subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual patients have a mix of immunologically different antibodies to the acetylcholine receptor. In addition, there is little similarity between patients with regard to AChR antibody subtypes. This is partly due to the heterogeneity of the receptor. The receptor of skeletal muscle consists of five different subunits, which associate to form a transmembrane ion channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/5\">",
"     5",
"    </a>",
"    ]. Individual variation can occur among patients and among muscles in the same patient. In addition, antibodies to the same receptor in a patient with myasthenia gravis can vary in their light-chain and subclass types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This heterogeneity has important implications for treatment, since it means that the B lymphocytes producing the AChR antibodies are also heterogeneous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     MuSK antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with myasthenia gravis who are seronegative for AChR antibodies have antibodies directed against another target on the surface of the muscle membrane, the muscle-specific receptor tyrosine kinase (MuSK) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. MuSK autoantibodies have been found in 40 to 70 percent of Caucasian patients with AChR-seronegative myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ], and a report from Japan showed a similar rate of MuSK positivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/12\">",
"     12",
"    </a>",
"    ]. The prevalence of MuSK antibody-positive myasthenia may be lower among Asians; a study from Taiwan found MuSK autoantibodies in only 4 percent of Chinese patients with AChR-seronegative myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Earlier reports found no MuSK autoantibodies in patients with myasthenia who were seropositive for AChR antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. However, using a recombinant human MuSK protein radioimmunoprecipitation assay, MuSK autoantibodies were detected in 10.5 percent of patients with AChR antibody-positive myasthenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MuSK antibody-positive myasthenia may have a different cause and pathologic mechanism than AChR-antibody positive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast to AChR antibody-positive myasthenia gravis, in which complement fixing IgG1 and IgG3 subclasses predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/14\">",
"     14",
"    </a>",
"    ], MuSK antibodies are mainly IgG4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/10\">",
"     10",
"    </a>",
"    ], the IgG subtype that does not activate complement. However, there is evidence that IgG1 subclass antibodies are also present at a low concentration and are capable of activating complement when bound to MuSK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/15\">",
"     15",
"    </a>",
"    ]. This may account for some of the pathology associated with MuSK antibodies.",
"   </p>",
"   <p>",
"    The MuSK protein is a transmembrane component of the postsynaptic neuromuscular junction. During neuromuscular junction formation, the MuSK complex mediates the clustering of AChRs that is induced by a nerve-derived proteoglycan called agrin, which binds to lipoprotein-related protein 4 (LRP4), leading to the activation of MuSK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/16\">",
"     16",
"    </a>",
"    ]. Activated MuSK interacts with the cytoplasmic adaptor protein Dok7 and initiates intracellular signalling systems that recruit AChR binding proteins including rapsyn to promote clustering of AChRs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In addition, the collagen Q tail of acetylcholinesterase binds to perlecan and MuSK, thereby anchoring acetylcholinesterase to the neuromuscular junction (",
"    <a class=\"graphic graphic_figure graphicRef50624 \" href=\"mobipreview.htm?1/0/1024\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. MuSK is also expressed in the mature neuromuscular junction and is likely important for its maintenance. Thus, it is biologically plausible that MuSK autoantibodies could produce myasthenia. However, the role of anti-MuSK antibodies in the pathogenesis of myasthenia gravis is not fully understood. The following reports illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoantibodies to the extracellular domain of MuSK strongly inhibit MuSK function in cultured myotubes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In animal models, active immunization with various purified extracellular MuSK domains is associated with the development of MuSK autoantibodies, myasthenic weakness, electromyographic evidence of a postsynaptic neuromuscular junction disorder, reduced AChR clustering, and other morphologic disruptions of the neuromuscular junction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Passive transfer of IgG from patients with MuSK-antibody positive and AChR-antibody negative myasthenia gravis into mice reduced the density of the postsynaptic AChR and disrupted the neuromuscular junction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one patient with AChR antibody-negative myasthenia and a high titer of MuSK autoantibodies, no evidence supporting MuSK antibodies as the cause of myasthenic symptoms was found despite comprehensive immunohistochemistry, electron microscopy, and electrophysiologic methods [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/24\">",
"       24",
"      </a>",
"      ]. Nevertheless, the amplitudes of miniature end plate potentials were reduced compared with normal values on in vitro electrophysiologic study of muscle biopsy from this patient.",
"     </li>",
"     <li>",
"      A report that examined muscle biopsies from 10 patients who had MuSK antibodies with AChR antibody-negative myasthenia gravis found that MuSK antibodies were not associated with loss of AChR at the end plate, complement deposition, or morphologic damage on muscle biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study demonstrated reduced amplitude of miniature end plate potentials using in-vitro electrophysiologic study of a muscle biopsy specimen from a patient with MuSK myasthenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/26\">",
"       26",
"      </a>",
"      ]. Histologic examination revealed some areas of partially denervated endplates and other areas with some degenerating postsynaptic folds.",
"     </li>",
"     <li>",
"      Human IgG purified from patients with MuSK-antibody positive myasthenia interferes with the binding of the collagen Q subunit of acetylcholinesterase to MuSK receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/27\">",
"       27",
"      </a>",
"      ]. Other experimental studies have shown that AChR clustering is perturbed in the absence of collagen Q [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/28\">",
"       28",
"      </a>",
"      ], suggesting that a similar mechanism is important in the pathogenesis of MuSK antibody related myasthenia gravis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are important differences between MuSK- and AChR- antibody positive myasthenia gravis in clinical features, including symptom complex and response to pharmacologic treatment with acetylcholinesterase inhibitors, glucocorticoids, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/29\">",
"     29",
"    </a>",
"    ]. These are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of myasthenia gravis\", section on 'MuSK antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Double-seronegative myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term seronegative myasthenia gravis (SNMG), also called antibody-negative myasthenia gravis, originally referred to patients with myasthenia gravis who had negative standard assays for AChR antibodies. As testing for MuSK antibodies became more prevalent, a subset of patients with myasthenia gravis who had no detectable antibodies directed to AChR or MuSK was observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/30\">",
"     30",
"    </a>",
"    ]. This group of patients is increasingly referred to as having double-seronegative myasthenia gravis, although some still use the term seronegative to mean the absence of both AChR and MuSK antibodies. Double-seronegative myasthenia gravis is an autoimmune disorder with most of the same features as seropositive myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The electrophysiologic findings are identical.",
"   </p>",
"   <p>",
"    Antibodies to lipoprotein-related protein 4 (LRP4), the agrin-binding receptor of the MuSK complex (",
"    <a class=\"graphic graphic_figure graphicRef50624 \" href=\"mobipreview.htm?1/0/1024\">",
"     figure 1",
"    </a>",
"    ), have been found in up to 50 percent of patients with double-seronegative myasthenia gravis, ie, those who lack both AChR and MuSK antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. In the two largest studies, autoantibodies to LRP4 were detected in 2 and 9 percent, respectively, of such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. These antibodies are primarily of the IgG1 subclass capable of activating complement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, they inhibit the binding of LRP4 with neural agrin and disrupt agrin-induced AChR clustering in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. Therefore, it is plausible that antibodies to LRP4 are pathogenic in some cases of double-seronegative myasthenia gravis. However, additional research is needed to confirm this hypothesis.",
"   </p>",
"   <p>",
"    Standard assays for AChR antibodies may fail to detect some patients with AChR-antibody related MG due to suboptimal sensitivity. However, when tested by a specialized cell-based immunofluorescence assay, up to one-half of patients with double-seronegative MG by standard assays have clustered AChR antibodies (also called low-affinity AChR antibodies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/15,36\">",
"     15,36",
"    </a>",
"    ]. These clustered AChR antibodies bind to high densities of AChRs as found at the neuromuscular junction. They can activate complement and passively transfer disease to mice. However, the assay for clustered AChR antibodies is not widely available, and the role of these antibodies in the pathogenesis of MG requires further confirmation.",
"   </p>",
"   <p>",
"    Other studies have identified antibodies to various intracellular muscle proteins, including the ryanodine receptor, titin, myosin, alpha actin, actin, rapsyn, and gravin, in both seropositive and seronegative myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. However, it remains problematic how antibodies against these proteins can produce their effects in intact muscle cells. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'The thymus and the origin of autoimmunity in myasthenia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T lymphocytes are also important in myasthenia gravis. They are not found in pathologic specimens, suggesting that they do not act as effector cells. They can, however, bind to the acetylcholine receptor and their main role is thought to be stimulation of B cell antibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/40\">",
"     40",
"    </a>",
"    ]. As with AChR antibodies, T cell binding is heterogeneous, a factor that must be addressed by immunotherapy.",
"   </p>",
"   <p>",
"    Anti-T cell receptor antibodies may play a role in immunoregulation in myasthenia. This was illustrated by a study of 40 patients that compared their specific anti-T cell receptor (anti-v-beta-5.1) circulating IgG antibody levels to those of healthy and other disease controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/41\">",
"     41",
"    </a>",
"    ]. While there was an overall increase in the mean antibody titer in those with myasthenia versus controls, there was an inverse correlation between the severity of myasthenia and the antibody titer. Among those with mild, versus moderate or severe disease, elevated titers of anti-v-beta 5.1 antibody were present in 92 and 11 percent of patients, respectively. This finding has suggested the possibility that measures that could increase antibodies to potentially pathogenic T cell receptors might have a role in therapy of myasthenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     The thymus and the origin of autoimmunity in myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with AChR antibody-positive myasthenia gravis have thymic abnormalities: hyperplasia in 60 to 70 percent and thymoma in 10 to 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, the disease often improves or disappears after thymectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, the thymus has been evaluated as a possible source of antigen to drive this autoimmune disease.",
"   </p>",
"   <p>",
"    The thymus contains a small number of \"myoid\" cells. These cells are distinguished by striations and the presence of acetylcholine receptors (AChR) on their surface and are the only known cells to express intact AChR outside of muscle. In addition, thymic epithelial cells produce unfolded AChR subunits that are hypothesized to prime helper T cells. These \"autoimmunized\" T cells then attack the AChR on myoid cells and create infiltrating germinal centers in the hyperplastic thymus where deposition of complement is found associated with the myoid cells. The autoimmunization completes as the antibodies in the germinal centers diversify to recognize intact muscle AChR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Thus, all of the elements necessary to produce and promote autoimmunity reside in microenvironments in the hyperplastic thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigen presentation by thymic cells via MHC class II molecules may be abnormal in patients with myasthenia. In particular, overexpression of cathepsin V, one of the enzymes responsible for cleaving the invariant chain that occupies the antigen presenting cleft of the MHC type II molecule, has been noted in the thymic tissue of patients with myasthenia and thymoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/45\">",
"     45",
"    </a>",
"    ]. Increased production of this enzyme is present in the frankly neoplastic thymic tissue as well as in area of inflamed gland (thymitis). Expression of mRNA and cathepsin V protein are not increased in the thymic tissue of patients with thymomas who do not have myasthenia. Other than the important role of the cathepsins in antigen processing cells, a link between enzyme overexpression and autoantibody production is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25432?source=see_link&amp;anchor=H10#H10\">",
"     \"Antigen presenting cells\", section on 'Antigen processing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25432?source=see_link&amp;anchor=H11#H11\">",
"     \"Antigen presenting cells\", section on 'Loading of MHC II molecules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It seems likely that genetic factors also contribute to the pathogenesis of myasthenia gravis. Certain HLA types have been associated with myasthenia, including HLA-B8, DRw3, and DQw2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/46\">",
"     46",
"    </a>",
"    ]. MuSK antibody-positive myasthenia is associated with haplotypes DR14 and DQ5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/47\">",
"     47",
"    </a>",
"    ]. Although the factors that initiate and maintain the immune response in MG are unknown, there is some evidence that Epstein-Barr virus (EBV) may play a role. One study found active EBV infection in the thymus of all 17 patients with MG and in none of six control patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, patients with myasthenia frequently have other immune-mediated diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves' disease, and thyroiditis, and a family history of autoimmune disorders.",
"   </p>",
"   <p>",
"    The role of thymoma in autoimmunity is not as clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/42\">",
"     42",
"    </a>",
"    ]. It is unknown why some patients with thymoma develop myasthenia while others do not:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The subtype of thymoma may be important; the development of myasthenia was significantly associated with mixed thymomas, but not with thymomas of the cortical type [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=see_link\">",
"       \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/43/4794?source=see_link\">",
"       \"Pathology of mediastinal tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to AChR antibodies, some individuals with thymoma have muscle autoantibodies directed against titin or the ryanodine receptor as well as other intracellular muscle proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/50-52\">",
"       50-52",
"      </a>",
"      ]. Among patients with myasthenia gravis, the presence of antititin antibodies is predictive of a thymic epithelial tumor (sensitivity 69 to 80 percent and specificity 90 to 100 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/50,53\">",
"       50,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have late onset myasthenia without thymoma may also have titin or ryanodine receptor antibodies. There is some suggestion that these antibodies may be associated with worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/52,54\">",
"     52,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, because AChR antibody levels do not clearly correlate with myasthenia gravis severity, investigators have continued to search for additional factors (eg, other muscle antibodies, secondary cytokines, chemokines) that might positively correlate with the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/55\">",
"     55",
"    </a>",
"    ]. As examples, the chemokines CXCL13 and CCL21 are overexpressed in hyperplastic thymus from individuals with MG and may play a pathologic role in the recruitment of lymphocytes to the MG thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. As another example, one study exposed cultured human muscle cells to sera from patients with myasthenia gravis of varying severity and observed a direct cytotoxic effect of the sera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/57\">",
"     57",
"    </a>",
"    ]. This cytotoxic effect was not complement dependent, and ryanodine and titin antibodies were not consistently detected in all sera, suggesting the effect may not be autoantibody mediated. However, the cytotoxic effect correlated with disease severity, making this an interesting phenomenon for further investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31287/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110405203\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myasthenia gravis is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles due to dysfunction of the neuromuscular junction. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myasthenia gravis is a condition that fulfills all the major criteria for a disorder mediated by autoantibodies against the acetylcholine receptor (AChR). However, the linkage between AChR antibodies and myasthenia gravis is not absolute; accumulating evidence suggests that autoantibodies directed against MuSK and perhaps other postsynaptic neuromuscular junction components have a pathogenic role in the development of myasthenia gravis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individual patients have a mix of immunologically different antibodies to the AChR. This is partly due to the heterogeneity of the receptor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acetylcholine receptor antibody subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with myasthenia gravis who are seronegative for AChR antibodies have antibodies directed against another target on the surface of the muscle membrane, the muscle-specific receptor tyrosine kinase (MuSK). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'MuSK antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Double-seronegative myasthenia gravis, also called antibody-negative myasthenia gravis, refers to the 6 to 12 percent of patients with myasthenia gravis who have negative standard assays for both AChR antibodies and MuSK antibodies. Double-seronegative myasthenia gravis is an autoimmune disorder with most of the same features as seropositive myasthenia gravis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Double-seronegative myasthenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T lymphocytes are also important in myasthenia gravis; they can bind to the acetylcholine receptor and their main role is thought to be stimulation of B cell antibody production. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Role of T cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with AChR antibody-positive myasthenia gravis have thymic abnormalities: hyperplasia in 60 to 70 percent and thymoma in 10 to 12 percent. Furthermore, the disease often improves or disappears after thymectomy. As a result, the thymus has been evaluated as a possible source of antigen to drive this autoimmune disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'The thymus and the origin of autoimmunity in myasthenia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/1\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/2\">",
"      Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/3\">",
"      Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982; 307:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/4\">",
"      Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987; 505:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/5\">",
"      Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 1995; 15:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/6\">",
"      Vincent A, Whiting PJ, Schluep M, et al. Antibody heterogeneity and specificity in myasthenia gravis. Ann N Y Acad Sci 1987; 505:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/7\">",
"      Nielsen FC, R&oslash;dgaard A, Djurup R, et al. A triple antibody assay for the quantitation of plasma IgG subclass antibodies to acetylcholine receptors in patients with myasthenia gravis. J Immunol Methods 1985; 83:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/8\">",
"      Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/9\">",
"      Vincent A, McConville J, Farrugia ME, et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003; 998:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/10\">",
"      McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/11\">",
"      Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002; 25:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/12\">",
"      Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004; 62:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/13\">",
"      Yeh JH, Chen WH, Chiu HC, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 2004; 62:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/14\">",
"      R&oslash;dgaard A, Nielsen FC, Djurup R, et al. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 1987; 67:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/15\">",
"      Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008; 131:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/16\">",
"      Ghazanfari N, Fernandez KJ, Murata Y, et al. Muscle specific kinase: organiser of synaptic membrane domains. Int J Biochem Cell Biol 2011; 43:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/17\">",
"      Bergamin E, Hallock PT, Burden SJ, Hubbard SR. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol Cell 2010; 39:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/18\">",
"      Okada K, Inoue A, Okada M, et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006; 312:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/19\">",
"      Cartaud A, Strochlic L, Guerra M, et al. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Biol 2004; 165:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/20\">",
"      Peng HB, Xie H, Rossi SG, Rotundo RL. Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan. J Cell Biol 1999; 145:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/21\">",
"      Shigemoto K, Kubo S, Maruyama N, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006; 116:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/22\">",
"      Richman DP, Nishi K, Morell SW, et al. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol 2012; 69:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/23\">",
"      Cole RN, Reddel SW, Gerv&aacute;sio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008; 63:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/24\">",
"      Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004; 62:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/25\">",
"      Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005; 57:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/26\">",
"      Niks EH, Kuks JB, Wokke JH, et al. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve 2010; 42:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/27\">",
"      Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011; 77:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/28\">",
"      Sigoillot SM, Bourgeois F, Lambergeon M, et al. ColQ controls postsynaptic differentiation at the neuromuscular junction. J Neurosci 2010; 30:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/29\">",
"      Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/30\">",
"      Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007; 36:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/31\">",
"      Sanders DB, Andrews PI, Howard Jr JF, Massey JM. Seronegative myasthenia gravis. Neurology 1997; 48:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/32\">",
"      Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007; 68:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/33\">",
"      Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/34\">",
"      Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/35\">",
"      Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/36\">",
"      Jacob S, Viegas S, Leite MI, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012; 69:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/37\">",
"      Ohta M, Ohta K, Itoh N, et al. Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: identification of anti-myosin, actomyosin, actin, and alpha-actinin antibodies by a solid-phase radioimmunoassay and a western blotting analysis. Clin Chim Acta 1990; 187:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/38\">",
"      Nauert JB, Klauck TM, Langeberg LK, Scott JD. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol 1997; 7:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/39\">",
"      Agius MA, Zhu S, Kirvan CA, et al. Rapsyn antibodies in myasthenia gravis. Ann N Y Acad Sci 1998; 841:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/40\">",
"      Yi Q, Pirskanen R, Lefvert AK. Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J Neuroimmunol 1993; 42:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/41\">",
"      Jambou F, Zhang W, Menestrier M, et al. Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis. J Clin Invest 2003; 112:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/42\">",
"      Willcox N, Leite MI, Kadota Y, et al. Autoimmunizing mechanisms in thymoma and thymus. Ann N Y Acad Sci 2008; 1132:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/43\">",
"      Leite MI, Jones M, Str&ouml;bel P, et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007; 171:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/44\">",
"      Hohlfeld R, Wekerle H. Reflections on the \"intrathymic pathogenesis\" of myasthenia gravis. J Neuroimmunol 2008; 201-202:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/45\">",
"      Tolosa E, Li W, Yasuda Y, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest 2003; 112:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/46\">",
"      Carlsson B, Wallin J, Pirskanen R, et al. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 1990; 31:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/47\">",
"      Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006; 66:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/48\">",
"      Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010; 67:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/49\">",
"      Wilisch A, Gutsche S, Hoffacker V, et al. Association of acetylcholine receptor alpha-subunit gene expression in mixed thymoma with myasthenia gravis. Neurology 1999; 52:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/50\">",
"      Voltz RD, Albrich WC, N&auml;gele A, et al. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 1997; 49:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/51\">",
"      Gautel M, Lakey A, Barlow DP, et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993; 43:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/52\">",
"      Romi F, Gilhus NE, Varhaug JE, et al. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003; 10:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/53\">",
"      Yamamoto AM, Gajdos P, Eymard B, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001; 58:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/54\">",
"      Romi F, Gilhus NE, Varhaug JE, et al. Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis. Ann N Y Acad Sci 2003; 998:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/55\">",
"      Meraouna A, Cizeron-Clairac G, Panse RL, et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006; 108:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/56\">",
"      Berrih-Aknin S, Ruhlmann N, Bismuth J, et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 2009; 66:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31287/abstract/57\">",
"      Luckman SP, Skeie GO, Helgeland G, Gilhus NE. Morphological effects of myasthenia gravis patient sera on human muscle cells. Muscle Nerve 2006; 33:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5153 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31287=[""].join("\n");
var outline_f30_35_31287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H110405203\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acetylcholine receptor antibody subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MuSK antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Double-seronegative myasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      The thymus and the origin of autoimmunity in myasthenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110405203\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5153|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/0/1024\" title=\"figure 1\">",
"      MuSK-LRP4-ColQ complex",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_35_31288="Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults";
var content_f30_35_31288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31288/contributors\">",
"     David Caro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31288/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31288/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/35/31288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first task of any clinician managing an acutely unstable patient is to secure the airway. In most circumstances, emergency clinicians use rapid sequence intubation (RSI) when active airway management is required. RSI incorporates neuromuscular blocking agents (NMBA) and rapidly acting sedative (ie, induction) agents to create optimal intubating conditions.",
"   </p>",
"   <p>",
"    This topic review will discuss the basic clinical pharmacology and selection of NMBAs for use in RSI. The practice of RSI and other medications used as part of RSI are discussed elsewhere, as are other aspects of airway management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38775?source=see_link\">",
"     \"Pretreatment agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NMBAS IN RAPID SEQUENCE INTUBATION (RSI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;RSI is the standard of care in emergency airway management for intubations not anticipated to be difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. RSI involves the use of a sedative and a neuromuscular blocking agent (NMBA) to render a patient rapidly unconscious and flaccid in order to facilitate emergent endotracheal intubation, mitigate unwanted physiologic responses to laryngoscopy and intubation, and minimize the risk of aspiration. Multiple prospective observational studies confirm the excellent success rate of RSI using the combination of a sedative and a NMBA in the emergency department (ED) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NMBAs are integral to the performance of RSI. Multiple observational studies demonstrate that the use of NMBAs improves success rates for emergency endotracheal intubation and reduces the risk of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/1,5-9\">",
"     1,5-9",
"    </a>",
"    ]. One prospective trial performed in a prehospital air medical setting and using a crossover design found the use of NMBAs improved the view of the larynx by a full grade in most patients when performing direct laryngoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In RSI, a NMBA is given in conjunction with a sedative agent. Patients undergoing RSI may be fully aware of their environment and painful stimuli, but unable to respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. If such patients are not adequately sedated, potentially adverse physiologic responses to airway manipulation can occur, including tachycardia, hypertension, and elevated intracranial pressure (ICP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/12\">",
"     12",
"    </a>",
"    ]. Sedative use prevents or minimizes these effects, and may also improve the laryngoscopic view obtained after neuromuscular paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to intubation, clinicians should whenever possible assess the patient's airway for potential management difficulty. Predicted airway difficulty may require modification of the intubation sequence, or avoidance of a NMBA altogether. Prediction and management of the difficult airway is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical circumstance may necessitate the use of a NMBA in a patient despite anticipation of a difficult airway. In such patients, the practitioner must anticipate a possible failure to visualize the glottis and pass an endotracheal tube. If the patient cannot be adequately oxygenated with a bag and mask or extraglottic airway device, decompensation can occur, requiring the placement of a surgical airway.",
"   </p>",
"   <p>",
"    Neurologic evaluation becomes more difficult after the use of NMBAs for RSI. However, pupillary response appears to be preserved in most such patients, according to a prospective study of 94 patients who received either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    as part of RSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular blocking agents (NMBA) are classified by their mechanism of action (ie, depolarizing or nondepolarizing). The only depolarizing agent in common clinical use is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      (SCh), the classic depolarizing agent, is an analogue of acetylcholine (ACh) that stimulates all cholinergic receptors throughout the parasympathetic and sympathetic nervous systems. SCh binds directly to the postsynaptic ACh receptors of the motor endplate, causing continuous stimulation of these receptors. This leads to transient fasciculations followed by muscular paralysis.",
"      <br/>",
"      <br/>",
"      Only a small percentage of SCh reaches the motor endplate. Most SCh is rapidly hydrolyzed in the bloodstream by the enzyme pseudocholinesterase. Paralysis persists until enough SCh dissociates from the ACh receptor and is hydrolyzed by pseudocholinesterase to allow normal receptor and motor endplate function.",
"     </li>",
"     <li>",
"      Nondepolarizing agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      ) competitively inhibit the postsynaptic ACh receptors of the neuromuscular motor endplate. This action prevents depolarization and inhibits all muscular function. Nondepolarizing NMBAs do not cause membrane depolarization, so the side effects seen with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      do not occur. The time to clinical effect and the duration of action are uniformly longer than SCh.",
"      <br/>",
"      <br/>",
"      Two categories of nondepolarizing NMBAs exist: the benzylisoquinolinium agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"       atracurium",
"      </a>",
"      and mivacurium) and the aminosteroid agents (eg, rocuronium,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"       pancuronium",
"      </a>",
"      ). The benzylisoquinolinium agents are not routinely used in the emergency setting because they more often cause histamine release and some cause autonomic ganglionic blockade. The aminosteroids are generally used in RSI when a contraindication to succinylcholine (SCh) exists and for prolonged neuromuscular paralysis after intubation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nondepolarizing agents'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUCCINYLCHOLINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    (SCh) is used extensively in the emergency setting, due to its rapidity of onset and offset, and the consistent intubating conditions it provides. For rapid sequence intubation (RSI), SCh is given as a 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenous dose, with intubation-level paralysis occurring 45 to 60 seconds after dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/17\">",
"     17",
"    </a>",
"    ]. Its duration of action is approximately 6 to 10 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of studies comparing SCh with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    for emergent intubation found that SCh more often creates excellent intubating conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/18\">",
"     18",
"    </a>",
"    ]. A subsequent meta-analysis found the two agents to be equivalent, but the doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (1 to 1.2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in several of the included studies were lower than our recommended dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/19\">",
"     19",
"    </a>",
"    ]. In clinical use, there likely is little difference between the agents, except for the substantially longer duration of action of rocuronium.",
"   </p>",
"   <p>",
"    It is far better to overestimate the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    than to underdose. Larger doses result in the same level of paralysis and do not increase the risk to the patient; inadequate doses can leave the patient inadequately paralyzed and difficult to intubate. Dosing of SCh is based on total body weight. This holds true in both morbidly obese and pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20329?source=see_link\">",
"     \"Emergency airway management in the morbidly obese patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCh can be used safely in patients with myasthenia gravis without risk of precipitating severe hyperkalemia. Patients with myasthenia gravis are relatively resistant to SCh, and when undergoing RSI should receive 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in order to stimulate sufficiently the remaining acetylcholine receptors unaffected by the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCh slowly degrades at room temperature, but retains 90 percent of its activity for up to three months when so stored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/23\">",
"     23",
"    </a>",
"    ]. The degradation rate can be reduced by refrigeration. If SCh is stored at room temperature, a quality management system is necessary to ensure removal of stock before the SCh becomes outdated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Contraindications and side effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Absolute contraindications overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    (SCh) is absolutely contraindicated in patients with a personal or family history of malignant hyperthermia and in patients deemed to be at high risk of developing severe hyperkalemia.",
"   </p>",
"   <p>",
"    We recommend the clinician use a nondepolarizing neuromuscular blocking agent, and not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , when performing RSI on patients with the following conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malignant hyperthermia history (personal or family) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36921?source=see_link\">",
"       \"Susceptibility to malignant hyperthermia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuromuscular disease involving denervation (SCh is safe in myasthenia gravis) (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical use'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Muscular dystrophy",
"     </li>",
"     <li>",
"      Stroke over 72 hours old",
"     </li>",
"     <li>",
"      Rhabdomyolysis",
"     </li>",
"     <li>",
"      Burn over 72 hours old",
"     </li>",
"     <li>",
"      Significant hyperkalemia (eg, suggested by characteristic changes on an electrocardiogram) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Hyperkalemia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Malignant hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCh can cause malignant hyperthermia in patients predisposed to the condition. Malignant hyperthermia is a myopathic metabolic disorder that is characterized by sympathetic hyperactivity, muscular rigidity, acidosis, and hyperthermia. Onset is usually acute, but delayed presentations can occur. The cause is thought to be related to abnormal intracellular calcium regulator proteins which result in abnormally high intracellular calcium levels. The disorder is estimated to occur in 0.0004 to 0.00625 percent of patients who receive SCh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/26\">",
"     26",
"    </a>",
"    ]. A history of malignant hyperthermia is an absolute contraindication to the use of SCh. This history is often unavailable prior to an emergent intubation. Malignant hyperthermia is treated with cooling techniques, sedation, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    sodium, 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36921?source=see_link\">",
"     \"Susceptibility to malignant hyperthermia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis, preexisting hyperkalemia associated with electrocardiographic changes, and disease states that cause upregulation of postjunctional acetylcholine receptors constitute the conditions that place patients at high risk of severe hyperkalemia (",
"    <a class=\"graphic graphic_table graphicRef74108 \" href=\"mobipreview.htm?8/21/8539\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fatal cases of hyperkalemia have occurred in patients with rhabdomyolysis given SCh. Standard treatment for hyperkalemia should be given, but is less effective in patients with hyperkalemia related to SCh and rhabdomyolysis than SCh and ACh receptor upregulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Receptor upregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upregulation of acetylcholine (ACh) receptors is the mechanism that increases the risk of severe hyperkalemia from SCh in susceptible patients. Such upregulation is perpetual in chronic conditions but is not clinically significant until approximately three to five days after an acute injury (eg, burn or crush). Receptor upregulation results from the disease states listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Denervating injuries (eg, stroke, spinal cord injury), after 72 hours",
"     </li>",
"     <li>",
"      Denervating diseases (eg, multiple sclerosis, amyotrophic lateral sclerosis)",
"     </li>",
"     <li>",
"      Inherited myopathies",
"     </li>",
"     <li>",
"      Burns, after 72 hours",
"     </li>",
"     <li>",
"      Crush injuries, after 72 hours",
"     </li>",
"     <li>",
"      Severe infection with exotoxin production (eg, tetanus, botulism)",
"     </li>",
"     <li>",
"      Prolonged total body immobilization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Receptor upregulation can take several days to develop, but once it is present hyperkalemia develops within a few minutes after SCh is given. Fatal episodes of hyperkalemia have occurred after doses of SCh in patients with upregulation of ACh receptors due to neuropathy (eg, following stroke) and myopathy (eg, muscular dystrophy). Some conditions (eg, muscular dystrophy, amyotrophic lateral sclerosis) result in lifelong receptor upregulation. Other diseases (eg, stroke, moderate or major burn) manifest receptor upregulation that can persist from six months to years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (SCh) is hyperkalemia. Studies suggest that SCh may raise the serum potassium up to 0.5",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    even in normal patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. This rise is clinically insignificant unless the patient is predisposed to severe hyperkalemia due to disease states that cause upregulation of postjunctional acetylcholine receptors or rhabdomyolysis (",
"    <a class=\"graphic graphic_table graphicRef74108 \" href=\"mobipreview.htm?8/21/8539\">",
"     table 1",
"    </a>",
"    ). If such a condition exists, SCh is contraindicated. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Receptor upregulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    SCh should also be avoided in the presence of hyperkalemia sufficient to cause electrocardiographic changes. A competitive (ie, nondepolarizing) NMBA is preferred when the risk of hyperkalemia is great. The ECG manifestations of hyperkalemia are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44069?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of hyperkalemia in adults\", section on 'ECG changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a number of case reports suggest that patients with chronically elevated serum potassium levels (eg, patients with renal failure on hemodialysis) are at risk for acute hyperkalemia if given SCh, a summary of several controlled studies suggests this is not true [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/31\">",
"     31",
"    </a>",
"    ]. SCh does not cause an abnormally large potassium increase in patients with renal failure (unlike neuromuscular disease). Nevertheless, it is prudent to avoid SCh if the serum potassium level is sufficiently elevated to cause electrocardiographic changes. We suggest using a nondepolarizing agent, and not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , when performing RSI in any patient who requires hemodialysis for treatment of renal failure and is suspected to have a significantly elevated serum potassium (eg, missed dialysis treatment with suggestive",
"    <span class=\"nowrap\">",
"     ECG).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Trismus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trismus/masseter",
"    muscle spasm occurs after SCh administration in 0.001 to 0.1 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Treatment consists of either a standard dose of a nondepolarizing neuromuscular blocking agent to relax the masseter muscles, or in extreme cases, a surgical airway (ie, cricothyrotomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Masseter spasm may occur in isolation or, rarely, with malignant hyperthermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/36\">",
"     36",
"    </a>",
"    ]. Unexplained hyperthermia and metabolic derangements in association with masseter spasm should raise suspicion for malignant hyperthermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fasciculations",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCh causes nicotinic activation that manifests as muscle fasciculations, along with muscarinic stimulation that may lead to bradycardia in selected patients, especially children. It is important to be prepared for both of these side effects. Muscle fasciculation may contribute to an increase in intracranial pressure. Fasciculations can be mitigated by giving a pretreatment dose of a nondepolarizing NMBA two to three minutes prior to giving SCh, but this is of no value in the emergency setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/37\">",
"     37",
"    </a>",
"    ]. A pretreatment dose is equivalent to one tenth the dose used for full paralysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link&amp;anchor=H8#H8\">",
"     \"Rapid sequence intubation in adults\", section on 'Pretreatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCh use in children has been questioned due to the small but important fraction of pediatric patients who have undiagnosed muscular dystrophy and are at risk for hyperkalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/38\">",
"     38",
"    </a>",
"    ]. Although SCh remains the preferred NMBA for emergent intubation during resuscitation of pediatric patients, the United States (US) Food and Drug Administration (FDA) has determined that SCh should not be used for elective surgery in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Succinylmonocholine, the initial metabolite of SCh, sensitizes the cardiac muscarinic receptors in the sinus node, and repeat doses of SCh may cause bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/39\">",
"     39",
"    </a>",
"    ]. Bradycardia in children has been described, but the attribution of this effect to SCh is controversial. Pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    may help to prevent this side effect, although no large randomized trials have been performed to assess this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/16\">",
"     16",
"    </a>",
"    ]. Bradycardia may also occur in adults who receive a second dose of SCh or a prolonged infusion. Clinicians should be prepared to administer atropine to any child or adult receiving SCh if bradycardia occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intraocular pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraocular pressure rises have been purported to result from SCh, but evidence for this is lacking and many patients with globe injuries are managed safely using SCh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. We feel it is acceptable for emergency clinicians to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    in open globe injuries. The use of sedative agents may mitigate any rise in intraocular pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link\">",
"     \"Open globe injuries: Emergent evaluation and initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For RSI in such patients, we suggest proper induction with a sedative agent and paralysis with a competitive NMBA or pretreatment with a defasciculating dose of a nondepolarizing agent in advance of SCh. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link&amp;anchor=H8#H8\">",
"     \"Rapid sequence intubation in adults\", section on 'Pretreatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NONDEPOLARIZING AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Common agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest nondepolarizing neuromuscular blocking agents (NMBAs) be used for rapid sequence intubation (RSI) when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (SCh) is contraindicated or when prolonged neuromuscular blockade is required. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Contraindications and side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When a nondepolarizing NMBA is indicated to perform RSI, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    be used. Rocuronium has a shorter time to onset and shorter duration of action compared with other agents in its class. Its time to intubation-level paralysis is approximately 45 to 60 seconds, when the recommended dose of 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV is given. Multiple studies and systematic reviews demonstrate it creates intubating conditions comparable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Rocuronium's duration of action with this dose is approximately 45 minutes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     Vecuronium",
"    </a>",
"    is an alternative competitive NMBA to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    for RSI. When vecuronium is used, a priming dose of 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is administered three minutes before an increased intubating dose of 0.15",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Used in this way, vecuronium achieves intubation level paralysis in approximately 75 to 90 seconds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     Pancuronium",
"    </a>",
"    should not be used for RSI. It can cause tachycardia and histamine release, and has a longer time to onset and duration of action than alternative agents.",
"   </p>",
"   <p>",
"    A predicted difficult airway is the most common relative contraindication to the use of nondepolarizing NMBAs for RSI. Should the preintubation examination predict a difficult airway, the clinician may select an alternative method to RSI, modify the RSI sequence, or develop a more detailed back-up plan in the event of a failed intubation. It is best to avoid a situation where intubation cannot be performed and the patient is apneic. Assessment and management of the difficult airway are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nondepolarizing NMBAs, unlike SCh, can be reversed by the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    (0.06 to 0.08",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) after approximately 40 percent of neuromuscular function has returned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/26\">",
"     26",
"    </a>",
"    ]. Neostigmine is an acetylcholinesterase inhibitor which allows ACh to continue to stimulate the neuromuscular junction and cause muscular stimulation, thereby competing more effectively with the nondepolarizing NMBA. Reversal is rarely indicated or of use in the emergent setting; however, due to the threshold for return of neuromuscular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sugammadex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sugammadex is a novel agent capable of rapidly reversing the neuromuscular blocking effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Several phase III clinical trials have been completed with favorable results and others are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/49\">",
"     49",
"    </a>",
"    ]. If further trials are successful, sugammadex may provide new options in the use of rocuronium for RSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/50\">",
"     50",
"    </a>",
"    ]. Sugammadex has been approved for use by the European Medicines Agency and a systematic review found it to be safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31288/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid sequence intubation (RSI) is the standard of care in emergency airway management for intubations not anticipated to be difficult. RSI involves combining a sedative and a neuromuscular blocking agent (NMBA) to render a patient rapidly unconscious and flaccid in order to facilitate emergent endotracheal intubation and to minimize the risk of aspiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NMBAs are integral to the performance of RSI. Use of NMBAs improves success rates for emergency endotracheal intubation and reduces the risk of complications. The mechanisms of these agents are described above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'NMBAs in Rapid Sequence Intubation (RSI)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When not contraindicated, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      (SCh) be used as the NMBA in RSI due to its rapidity of onset and offset, and the consistent intubating conditions it provides (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). SCh is given as a 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV dose in adults. Intubation-level paralysis is achieved within 45 to 60 seconds and its duration of action is approximately 6 to 10 minutes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using a nondepolarizing NMBA, and not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      , when performing RSI on patients with the following conditions (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Malignant hyperthermia history (personal or family)",
"     </li>",
"     <li>",
"      Neuromuscular disease",
"     </li>",
"     <li>",
"      Muscular dystrophy",
"     </li>",
"     <li>",
"      Stroke over 72 hours old",
"     </li>",
"     <li>",
"      Rhabdomyolysis",
"     </li>",
"     <li>",
"      Burn over 72 hours old",
"     </li>",
"     <li>",
"      Significant hyperkalemia (eg, suggested by characteristic changes on an electrocardiogram)",
"      <br/>",
"      <br/>",
"      The contraindications to SCh are discussed in detail in the text. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Absolute contraindications overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Contraindications and side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      (SCh) is contraindicated for rapid sequence intubation (RSI), we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      be used over other nondepolarizing NMBAs (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Rocuronium is given as a 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV dose. The time to intubation-level paralysis is approximately 45 to 60 seconds, and its duration of action with this dose is approximately 45 minutes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nondepolarizing agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/1\">",
"      Li J, Murphy-Lavoie H, Bugas C, et al. Complications of emergency intubation with and without paralysis. Am J Emerg Med 1999; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/2\">",
"      Sagarin MJ, Chiang V, Sakles JC, et al. Rapid sequence intubation for pediatric emergency airway management. Pediatr Emerg Care 2002; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/3\">",
"      Sakles JC, Laurin EG, Rantapaa AA, Panacek EA. Airway management in the emergency department: a one-year study of 610 tracheal intubations. Ann Emerg Med 1998; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/4\">",
"      Tayal VS, Riggs RW, Marx JA, et al. Rapid-sequence intubation at an emergency medicine residency: success rate and adverse events during a two-year period. Acad Emerg Med 1999; 6:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/5\">",
"      Cicala R, Westbrook L. An alternative method of paralysis for rapid-sequence induction. Anesthesiology 1988; 69:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/6\">",
"      Bozeman WP, Kleiner DM, Huggett V. A comparison of rapid-sequence intubation and etomidate-only intubation in the prehospital air medical setting. Prehosp Emerg Care 2006; 10:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/7\">",
"      Ma OJ, Atchley RB, Hatley T, et al. Intubation success rates improve for an air medical program after implementing the use of neuromuscular blocking agents. Am J Emerg Med 1998; 16:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/8\">",
"      Vijayakumar E, Bosscher H, Renzi FP, et al. The use of neuromuscular blocking agents in the emergency department to facilitate tracheal intubation in the trauma patient: help or hindrance? J Crit Care 1998; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/9\">",
"      Wilcox SR, Bittner EA, Elmer J, et al. Neuromuscular blocking agent administration for emergent tracheal intubation is associated with decreased prevalence of procedure-related complications. Crit Care Med 2012; 40:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/10\">",
"      Topulos GP, Lansing RW, Banzett RB. The experience of complete neuromuscular blockade in awake humans. J Clin Anesth 1993; 5:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/11\">",
"      Wagner BK, Zavotsky KE, Sweeney JB, et al. Patient recall of therapeutic paralysis in a surgical critical care unit. Pharmacotherapy 1998; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/12\">",
"      Sivilotti ML, Ducharme J. Randomized, double-blind study on sedatives and hemodynamics during rapid-sequence intubation in the emergency department: The SHRED Study. Ann Emerg Med 1998; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/13\">",
"      El-Orbany MI, Wafai Y, Joseph NJ, Salem MR. Does the choice of intravenous induction drug affect intubation conditions after a fast-onset neuromuscular blocker? J Clin Anesth 2003; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/14\">",
"      Sivilotti ML, Filbin MR, Murray HE, et al. Does the sedative agent facilitate emergency rapid sequence intubation? Acad Emerg Med 2003; 10:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/15\">",
"      Caro DA, Andescavage S, Akhlaghi M, et al. Pupillary response to light is preserved in the majority of patients undergoing rapid sequence intubation. Ann Emerg Med 2011; 57:234.",
"     </a>",
"    </li>",
"    <li>",
"     Walls RM. Manual of Emergency Airway Management, 4th, Walls RM, Murphy MF.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/17\">",
"      Naguib M, Samarkandi AH, El-Din ME, et al. The dose of succinylcholine required for excellent endotracheal intubating conditions. Anesth Analg 2006; 102:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/18\">",
"      Perry JJ, Lee JS, Sillberg VA, Wells GA. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2008; :CD002788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/19\">",
"      Herbstritt A, Amarakone K. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: is rocuronium as effective as succinylcholine at facilitating laryngoscopy during rapid sequence intubation? Emerg Med J 2012; 29:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/20\">",
"      Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/21\">",
"      Guay J, Grenier Y, Varin F. Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. Clin Pharmacokinet 1998; 34:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/22\">",
"      Levitan R. Safety of succinylcholine in myasthenia gravis. Ann Emerg Med 2005; 45:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/23\">",
"      Boehm JJ, Dutton DM, Poust RI. Shelf life of unrefrigerated succinylcholine chloride injection. Am J Hosp Pharm 1984; 41:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/24\">",
"      Gronert GA. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 2001; 94:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/25\">",
"      Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104:158.",
"     </a>",
"    </li>",
"    <li>",
"     Miller R. Miller's Anesthesia, 6th, Elsevier Churchill Livingstone, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/27\">",
"      Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982; 56:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/28\">",
"      Magee DA, Gallagher EG. \"Self-taming\" of suxamethonium and serum potassium concentration. Br J Anaesth 1984; 56:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/29\">",
"      Zink BJ, Snyder HS, Raccio-Robak N. Lack of a hyperkalemic response in emergency department patients receiving succinylcholine. Acad Emerg Med 1995; 2:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/30\">",
"      Raman SK, San WM. Fasciculations, myalgia and biochemical changes following succinylcholine with atracurium and lidocaine pretreatment. Can J Anaesth 1997; 44:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/31\">",
"      Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesth Analg 2000; 91:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/32\">",
"      Carroll JB. Increased incidence of masseter spasm in children with strabismus anesthetized with halothane and succinylcholine. Anesthesiology 1987; 67:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/33\">",
"      Sims C. Masseter spasm after suxamethonium in children. Br J Hosp Med 1992; 47:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/34\">",
"      Bauer SJ, Orio K, Adams BD. Succinylcholine induced masseter spasm during rapid sequence intubation may require a surgical airway: case report. Emerg Med J 2005; 22:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/35\">",
"      Gill M, Graeme K, Guenterberg K. Masseter spasm after succinylcholine administration. J Emerg Med 2005; 29:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/36\">",
"      Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility. Anesth Analg 1986; 65:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/37\">",
"      Harvey SC, Roland P, Bailey MK, et al. A randomized, double-blind comparison of rocuronium, d-tubocurarine, and \"mini-dose\" succinylcholine for preventing succinylcholine-induced muscle fasciculations. Anesth Analg 1998; 87:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/38\">",
"      Larach MG, Rosenberg H, Gronert GA, Allen GC. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila) 1997; 36:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/39\">",
"      Yasuda I, Hirano T, Amaha K, et al. Chronotropic effects of succinylcholine and succinylmonocholine on the sinoatrial node. Anesthesiology 1982; 57:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/40\">",
"      Vachon CA, Warner DO, Bacon DR. Succinylcholine and the open globe. Tracing the teaching. Anesthesiology 2003; 99:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/41\">",
"      Chidiac EJ, Raiskin AO. Succinylcholine and the open eye. Ophthalmol Clin North Am 2006; 19:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/42\">",
"      Perry JJ, Lee J, Wells G. Are intubation conditions using rocuronium equivalent to those using succinylcholine? Acad Emerg Med 2002; 9:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/43\">",
"      Nava-Ocampo AA, Vel&aacute;zquez-Armenta Y, Moyao-Garc&iacute;a D, Salmer&oacute;n J. Meta-analysis of the differences in the time to onset of action between rocuronium and vecuronium. Clin Exp Pharmacol Physiol 2006; 33:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/44\">",
"      Patanwala AE, Stahle SA, Sakles JC, Erstad BL. Comparison of succinylcholine and rocuronium for first-attempt intubation success in the emergency department. Acad Emerg Med 2011; 18:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/45\">",
"      Baumgarten RK, Carter CE, Reynolds WJ, et al. Priming with nondepolarizing relaxants for rapid tracheal intubation: a double-blind evaluation. Can J Anaesth 1988; 35:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/46\">",
"      Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/47\">",
"      Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/48\">",
"      Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/49\">",
"      Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/50\">",
"      Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31288/abstract/51\">",
"      Abrishami A, Ho J, Wong J, et al. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev 2009; :CD007362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 279 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31288=[""].join("\n");
var outline_f30_35_31288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NMBAS IN RAPID SEQUENCE INTUBATION (RSI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUCCINYLCHOLINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Contraindications and side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Absolute contraindications overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Receptor upregulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Trismus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fasciculations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Use in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intraocular pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NONDEPOLARIZING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Common agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sugammadex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/279\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/279|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8539\" title=\"table 1\">",
"      Succinylcholine hyperK",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20329?source=related_link\">",
"      Emergency airway management in the morbidly obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38775?source=related_link\">",
"      Pretreatment agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36921?source=related_link\">",
"      Susceptibility to malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_35_31289="Hepatitis C virus infection and renal transplantation";
var content_f30_35_31289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis C virus infection and renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31289/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31289/contributors\">",
"     Svetlozar Natov, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31289/contributors\">",
"     Brian JG Pereira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31289/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31289/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31289/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/35/31289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver disease is an important cause of morbidity and mortality among recipients of transplanted organs. Biochemical abnormalities in liver function are seen in 7 to 24 percent of transplant recipients, and liver failure is the cause of death in 8 to 28 percent of long-term survivors after renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, approximately one-half of the cases of liver disease among transplanted patients were attributed to a variety of etiologies, including viral infections such as hepatitis B virus (HBV), Epstein-Barr virus or cytomegalovirus, drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , hemosiderosis or alcohol. The remaining one-half of cases were attributed to non-A, non-B hepatitis (NANBH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cloning and characterization of hepatitis C virus has permitted the development and refinement of tests to detect antibodies to multiple HCV antigens (anti-HCV) and the presence and titer of HCV RNA. These modalities have opened avenues to the study of the prevalence, transmission, and natural course of HCV infection in transplant recipients.",
"   </p>",
"   <p>",
"    The clinical issues relating to HCV infection in renal transplantation are presented here. The role of HCV in causing renal disease in transplant recipients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATITIS C VIRUS AND TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have focused attention upon the extremely high rate of transmitted infection and the significant morbidity and mortality associated with HCV in the immunosuppressed transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This has forced national and international organ banks to examine their policies concerning transplantation in the patient infected with HCV and the allocation of organs from HCV positive or negative donors into HCV positive or negative recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence of HCV infection among donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to minimize the significant morbidity associated with the transplantation of organs from HCV positive donors rests upon the ability to accurately identify such donors. In turn, the detection of HCV infection among cadaver organ donors depends in part upon the type of laboratory test. As an example, the sensitivity of antibody or enzyme linked immunosorbent (ELISA) assays vary by generation of the antibody test; in addition, such assays only detect evidence of prior and not necessarily active transmissible infection. As a result, scarce organs may be unnecessarily discarded because of a positive ELISA assay but without evidence of transmissible viral particles as determined by a negative HCV RNA by polymerase chain reaction (PCR). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The positive and negative predictive values of antibody screening tests were examined in a large national collaborative study in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/9\">",
"     9",
"    </a>",
"    ]. This study involved 3078 cadaver organ donors from eight organ procurement organizations representing different geographical regions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of a positive first generation anti-HCV test (enzyme linked immunosorbent assay ELISA1) was 5.1 percent (range 1.5 to 16.7 percent).",
"     </li>",
"     <li>",
"      Sera from these ELISA1 positive donors and 100 randomly selected ELISA1 negative cadaver organ donors were then retrieved for anti-HCV testing by both a second generation test (ELISA2) and HCV RNA testing by PCR. Based upon these tests, the extrapolated prevalence of ELISA2 and HCV RNA among cadaver organ donors was calculated to be 4.2 percent and 2.4 percent, respectively. The positive and negative predictive values of ELISA2 were 55 and 100 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, discarding organs from ELISA2 positive donors would eliminate transmission of infection. However, of the 4.2 percent of anti HCV positive donor kidneys discarded, 1.8 percent would be wasted (anti-HCV positive, HCV RNA negative). Unfortunately, the detection of HCV RNA by PCR is impractical for the purposes of cadaver organ procurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators have suggested that, because of improved specificity, the use of third generation anti-HCV tests in donor screening could potentially minimize the loss of organs due to false positive results from screening assays for anti-HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/11\">",
"     11",
"    </a>",
"    ]. Using ELISA3, for example, there was a lower prevalence (3.7 percent) of anti-HCV among cadaver organ donors than the extrapolated prevalence (4.2 percent) of anti-HCV by ELISA2 among cadaver organ donors in the United States.",
"   </p>",
"   <p>",
"    In an attempt to minimize the waste of scarce organs, some investigators have suggested that anti-HCV positive donors with no history of drug abuse or homosexual lifestyle, absence of anti-HBs or anti-HBc antibodies, and normal serum alanine aminotransferase levels are at lower risk of transmitting disease and could therefore be used for transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, we have found that these characteristics do not distinguish anti-HCV positive donors with and without serum HCV RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, RIBA2 (which has been suggested as a confirmatory test in blood donors) is not specific enough to distinguish ELISA2 positive organ donors with and without HCV RNA. At present, we screen donors for anti-HCV and those that are positive are considered infectious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transmission of hepatitis C virus infection by organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies published the experience of the New England Organ Bank with organs harvested from HCV positive individuals from 1986 to 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In these studies, sera from 13 of 716 consecutive cadaver organ donors were found to be positive against HCV. The following findings were noted among the 29 recipients of organs from these donors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fourteen of the 29 (48 percent) developed posttransplantation NANBH.",
"     </li>",
"     <li>",
"      Two of the 14 with NANBH died from sub-fulminant liver failure; the remaining 12 (86 percent) developed chronic liver disease.",
"     </li>",
"     <li>",
"      Six of eight patients in whom liver pathology was available had evidence of chronic active hepatitis; the remaining two had cirrhosis.",
"     </li>",
"     <li>",
"      Among the 24 patients in whom posttransplantation sera were available, 16 (67 percent) tested positive for anti-HCV antibodies and 23 (96 percent) tested positive for HCV RNA by PCR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar studies have been undertaken by other organ procurement organizations and transplant centers. A synthesis of these studies reveals that among recipients of organs from anti-HCV positive donors, 0 to 55 percent develop post-transplant liver disease, 14 to 100 percent test positive for anti-HCV antibodies after transplantation, and 57 to 96 percent test positive for HCV RNA by PCR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical impact of transmission of HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have found that transplant patients who received organs from HCV positive donors suffer from higher rates of liver disease but not lower survival rates than transplant patients who received organs from negative donors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term studies from the New England Organ Bank have compared posttransplantation clinical outcomes in the 29 recipients of organs from the 13 anti-HCV positive cadaver organ donors to the outcomes of 74 recipients from 37 randomly selected anti-HCV negative donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/15\">",
"       15",
"      </a>",
"      ]. After a median follow-up of 42 and 49 months of recipients of organs from positive and negative donors respectively, the relative risk of liver disease was increased four-fold among recipients from anti-HCV positive donors. Four (14 percent) of the 29 patients died due to or with liver failure. There was, however, no increase in graft loss (relative risk 0.93) or death (relative risk 0.89) among recipients from anti-HCV positive donors.",
"      <br/>",
"      <br/>",
"      After extended follow-up (median, 68 months among recipients of organs from anti-HCV-positive donors and 70 months among recipients of organs from anti-HCV-negative donors), there continued to be no significant differences between groups with respect to graft loss or death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/16\">",
"       16",
"      </a>",
"      ]. Compared with recipients of organs from anti-HCV-negative donors, the relative risk of graft loss among recipients of organs from anti-HCV-positive donors was 0.95 (95 percent confidence intervals 0.54 to 1.67), and the relative risk of death was 1.00 (95 percent confidence intervals 0.49 to 2.02).",
"     </li>",
"     <li>",
"      Another report prospectively studied 42 anti-HCV negative recipients of kidneys from anti-HCV positive donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/17\">",
"       17",
"      </a>",
"      ]. At four years after transplant, the prevalence of liver disease was higher among recipients of positive kidneys than control patients, but survival among the two groups did not significantly differ.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have found that recipients of organs from anti-HCV positive donors had significant liver disease",
"    <strong>",
"     and",
"    </strong>",
"    decreased survival compared to organ recipients from negative donors. As an example, one prospective study transplanted 69 kidneys from anti-HCV positive donors into anti-HCV negative recipients who were considered to have a limited life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/18\">",
"     18",
"    </a>",
"    ]. After a short follow-up, one patient died of fulminant hepatitis and two patients developed cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, survival among recipients from anti HCV positive donors was significantly lower than in recipients from anti-HCV negative donors.",
"   </p>",
"   <p>",
"    Despite these possible adverse effects, there may be a survival advantage with receiving a kidney from an anti-HCV positive donor versus remaining on a wait-list. Among nearly 40,000 USRDS patients awaiting transplantation, transplantation with such a kidney was significantly associated with improved survival versus remaining on a transplant wait list (adjust hazard ratio 0.76) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, these data indicate a higher risk of liver disease among recipients of organs from anti-HCV positive donors, but (except for a few reports) no significant adverse effect on patient or graft survival. It is noteworthy, however, that cases of fulminant or subfulminant hepatitis have been reported only among patients who received organs from anti-HCV positive donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transplantation from anti-HCV positive donors into recipients with pretransplantation HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV has several distinct variants, which have been identified by sequence analysis of the viral genome and classified into six major types, one through six [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/20\">",
"     20",
"    </a>",
"    ]; each consists of one or more subtypes, named a, b, c, etc., in order of discovery. In addition, each subtype may include individual isolates. Because HCV does not provide protective immunity, transplant recipients with preexisting HCV infection may develop reinfection (new infection after a previous infection has cleared) with the same or different HCV strain or superinfection (infection with a new HCV strain in the presence of current infection) if transplanted with a kidney from a HCV infected donor. Therefore, among HCV RNA positive recipients of kidneys from HCV RNA positive donors, the viral genotype(s) found posttransplantation can be [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The same as the recipient's pretransplantation HCV genotype",
"     </li>",
"     <li>",
"      The same as the donor's HCV genotype",
"     </li>",
"     <li>",
"      Both individual's genotypes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical implications of superinfection of HCV in transplant recipients are not well defined. However, we have demonstrated that the type of HCV-infection, single versus mixed (infection with more than one HCV-genotype) does not adversely affect patient survival among renal transplant candidates (at least in the short-term) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/23\">",
"     23",
"    </a>",
"    ]. Furthermore, in a prospective study from Spain, there were no differences in the posttransplantation prevalence of liver disease, or graft or patient survival between 24 anti-HCV positive recipients who received kidneys from anti-HCV positive donors compared to 40 anti-HCV positive recipients of kidneys from anti-HCV negative donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/24\">",
"     24",
"    </a>",
"    ]. However, four of five anti-HCV positive but PCR negative recipients from PCR positive donors acquired HCV RNA. These data suggest that superinfections do occur, but they may not have any serious clinical consequences, at least in the short-term. Another study also demonstrated that transplantation of kidney from HCV seropositive donors in anti-HCV positive recipients was not associated with adverse post-transplant outcomes in the short term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The practice of using kidneys from HCV seropositive donors for transplantation in anti-HCV positive patients may offer some advantage. One study demonstrated that such practice shortened the waiting time for anti-HCV positive patients without increasing the rate of rejection episodes, infection complications, graft loss or patient death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Policies on the use of organs from donors with HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the high prevalence of HCV infection among recipients of organs from anti-HCV positive donors, several organ procurement organizations adopted a policy of testing all cadaver organ donors for anti-HCV and restricting the use of organs from anti-HCV positive donors to life-saving transplants (heart, liver, or lung) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Similar policies were recommended by the United States Public Health Service Inter-Agency Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a complete moratorium on transplantation of organs from anti-HCV positive donors into kidney transplant recipients may not be appropriate for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The wide range in the prevalence of liver disease and HCV infection after transplantation of organs from anti-HCV positive donors",
"     </li>",
"     <li>",
"      The absence of definitive evidence of a detrimental effect on patient survival",
"     </li>",
"     <li>",
"      The current shortage of cadaver kidneys",
"     </li>",
"     <li>",
"      The constantly growing waiting list for organ transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our view, short-term clinical data on outcomes among anti-HCV positive recipients of kidneys from anti-HCV positive donors as well as the evidence that mixed infections (HCV infections with more than one HCV-genotype) do not adversely affect survival among ESRD patients justify further study of the strategy of allocating kidneys from anti-HCV positive organ donors to anti-HCV positive transplant candidates.",
"   </p>",
"   <p>",
"    A better alternative seems to be a policy of transplanting kidneys from anti-HCV-positive donors to only HCV RNA-positive recipients. This approach is consistent with recommendations from the 2008 KDIGO guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary data from some transplant centers in Spain have demonstrated no differences in liver disease and patient survival between HCV RNA positive recipients of kidneys from anti-HCV positive donors and anti-HCV positive recipients of kidneys from anti-HCV negative donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/31\">",
"     31",
"    </a>",
"    ]. Data from a survey that included response from 147 of 245 renal transplant centers in the United States indicated that currently 49 percent of these centers use HCV seropositive donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of pretransplantation anti-HCV status on posttransplantation clinical outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are anti-HCV positive before transplantation have a significantly increased risk of posttransplant liver disease. Chronic active hepatitis and its sequelae are the principal forms of liver involvement in these patients. In addition, an unusual form of liver disease with severe cholestasis and rapidly progressive liver failure has been described in a few patients with hepatitis C infection who undergo renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/33\">",
"     33",
"    </a>",
"    ]. This condition, termed fibrosing cholestatic hepatitis, is characterized by prominent cholestasis and extensive fibrosis.",
"   </p>",
"   <p>",
"    Overall, posttransplant liver disease is an important clinical problem since 11 to 49 percent of renal transplant recipients are anti-HCV positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/34-42\">",
"     34-42",
"    </a>",
"    ]. Studies from the New England Organ Bank have shown that the relative risk of posttransplantation liver disease was 5.0 for recipients with anti-HCV prior to transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, a survey of related studies has revealed that posttransplant liver disease occurs among 19 to 64 percent of recipients with anti-HCV compared to only 1 to 30 percent among recipients without anti-HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/34,35,38,40,41,43\">",
"     34,35,38,40,41,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kidney transplantation in the patient previously infected with HCV is associated with increased proliferation of the virus, resulting in a 1.8 to 30.3-fold increase in serum viral titer. An increased viral titer, however, may not be associated with an increased risk of posttransplantation liver disease. Among patients with HCV RNA in the sera, the titer of HCV RNA was no different among patients with and without posttransplantation liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/34\">",
"     34",
"    </a>",
"    ]. Furthermore, the post-transplant viral load was similar in patients with mild histological changes on liver biopsy or chronic changes, and there was no association between the transaminase patterns and the viral load level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/44\">",
"     44",
"    </a>",
"    ]. These data suggest that factors other than the viral load determine the risk of liver disease among transplant recipients with HCV infection.",
"   </p>",
"   <p>",
"    The progression of liver injury may be slower in patients who undergo kidney transplantation compared to those on the kidney transplant waiting list. This was shown in retrospective analysis of sequential liver biopsies obtained before and after renal transplantation among 31 HCV-positive patients and compared to biopsies of 13 HCV-patients who remained on the waiting list [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/45\">",
"     45",
"    </a>",
"    ]. In general, patients on the waiting list were more likely to have progression of liver fibrosis (62 versus 23 percent among those who were transplanted).",
"   </p>",
"   <p>",
"    Although studies consistently show an increased risk of posttransplantation liver disease in anti-HCV positive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/46\">",
"     46",
"    </a>",
"    ], conflicting results surround the question as to whether this is associated with decreased survival. As an example, three studies failed to detect significant differences in patient survival between recipients with and without anti-HCV prior to renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/35,38,40\">",
"     35,38,40",
"    </a>",
"    ]. In another study, only HCV infection acquired in the post-transplant period was associated with a higher mortality, with pretransplantation HCV infection having no adverse impact on patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, several studies have shown lower survival with pretransplant evidence of hepatitis C infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/34,41,47-50\">",
"     34,41,47-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the New England Organ Bank revealed that recipients with pretransplantation anti-HCV had a 3.3-fold higher risk of death and a 9.9-fold higher risk of death due to sepsis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study from France evaluated almost 500 hepatitis B virus-negative patients with renal failure who subsequently underwent transplantation; survival and the causes of death posttransplant were compared among anti-HCV positive and negative patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/48\">",
"       48",
"      </a>",
"      ]. Multivariate analysis found that hepatitis C virus infection was associated with a significant increase in the mortality rate (odds ratio of 2.8). The enhanced mortality was principally due to liver disease and sepsis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To better assess the effects of hepatitis C virus on outcomes post-transplant, a 2005 meta-analysis was performed of eight clinical trials that included 6365 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/51\">",
"     51",
"    </a>",
"    ]. The presence of anti-HCV antibodies increased the risk for death (relative risk of 1.79, 95% CI 1.57-2.03) and allograft failure (relative risk of 1.56, 95% CI 1.35-1.80) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/51\">",
"     51",
"    </a>",
"    ]. Hepatic cancer and cirrhosis were significantly more frequent causes of death in those with anti-HCV antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effect of HCV genotype on survival after renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data concerning the impact of different HCV genotypes on survival after transplantation. Data from the New England Organ Bank revealed that patient survival did not vary significantly with genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the genotype distribution and the number of patients evaluated were small. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29780?source=see_link\">",
"     \"Characteristics of the hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect of HCV infection upon survival with dialysis or renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the presence of anti-HCV antibodies at the time of renal transplantation may be associated with an increased risk of death, it is not yet known whether survival for anti-HCV positive patients is greater with renal replacement therapy with dialysis or with transplantation.",
"   </p>",
"   <p>",
"    Some studies suggest that renal transplantation may result in better survival than dialysis among anti-HCV positive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/45,52-54\">",
"     45,52-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A New England Organ Bank study evaluated the relative risk of death among patients with or without anti-HCV antibodies who were placed on a renal transplant waiting list and either did or did not receive a renal allograft [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/52\">",
"       52",
"      </a>",
"      ]. Among all patients, transplantation was associated with enhanced survival compared to continued dialysis (p&lt;0.0001). The relative risk of death for transplantation versus dialysis was 4.75, 1.76, 0.31, and 0.84 at follow-up periods of zero to three months, three to six months, seven months to four years, and after four years, respectively. At all time periods, the relative risk of death was similar between those with and without anti-HCV antibodies. Thus, transplantation resulted in a long-term survival benefit among the patients who were anti-HCV positive.",
"     </li>",
"     <li>",
"      Similar findings were noted in another report that compared survival among anti-HCV positive patients who underwent renal transplantation with anti-HCV positive individuals who were acceptable for transplant but had not yet undergone the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/53\">",
"       53",
"      </a>",
"      ]. Outcomes were assessed in patients with at least two years of follow-up information. Despite similar comorbid clinical features, patients in whom renal transplantation had been performed had a lower mortality than those remaining on dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that the possible detrimental effect of transplantation on the course of HCV infection does not outweigh its long-term beneficial effect on survival in ESRD. Thus, anti-HCV positive status alone should not be considered a contraindication for renal transplantation",
"   </p>",
"   <p>",
"    Liver damage as determined by histologic severity is a strong predictor of liver failure and death after transplantation. As a result, in anti-HCV positive patients",
"    <strong>",
"     without",
"    </strong>",
"    evidence of liver disease and in the absence of definite studies demonstrating worse outcomes after renal transplantation, we suggest that such patients should be allowed to make an informed choice of staying on dialysis or undergoing transplantation. However, transplant recipients can have histological evidence of liver disease in the absence of elevated serum ALT levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, there may be merit in a policy to perform liver biopsies on all anti-HCV positive patients awaiting renal transplantation to accomplish accurate histopathological evaluation. In patients with histological evidence of liver disease, the decision to proceed with renal transplantation should be made cautiously, since immunosuppression may increase viral replication and possibly exacerbate liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without renal disease, the administration of interferon alfa (IFNa) in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has been approved for both initial treatment and treatment of relapse of chronic hepatitis C. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .) However, the clearance of ribavirin is impaired in patients with renal dysfunction and the drug and its metabolites are not removed by hemodialysis. Thus, ribavirin is not recommended for patients with a creatinine clearance",
"    <strong>",
"     below",
"    </strong>",
"    50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interferon alfa after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    major stumbling block to the use of IFNa in renal transplant recipients has been the onset of acute rejection with IFN treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In addition to antiviral activity, IFNa has pleiotropic effects including antiproliferative and immunomodulatory properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/58\">",
"     58",
"    </a>",
"    ]. IFNa also induces cytokine gene expression, increased cell surface expression of HLA antigens, and enhanced function of natural killer cells, cytotoxic T cells, and monocytes.",
"   </p>",
"   <p>",
"    These immunostimulant effects can result in enhanced allograft rejection when IFNa is used in the transplant recipient with CMV or hepatitis C. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of IFNa as prophylaxis against CMV disease in renal transplant recipients has been associated with a high incidence of steroid-resistant allograft rejection resulting in graft loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. One study of 50 such patients found that immunoprophylaxis with IFNa was associated with six cases of rejection (12 percent) resulting in allograft loss versus no losses in those in whom immunoprophylaxis was not administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A majority of studies have observed an increased risk of acute rejection (40 percent to 100 percent) among renal transplant recipients treated with IFNa for chronic liver disease due to hepatitis C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/61-65\">",
"       61-65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, another study did not observe allograft rejection in six renal transplant recipients treated with IFNa 2 to 15 years after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/66\">",
"     66",
"    </a>",
"    ]. These patients had stable renal function for several years prior to the start of IFNa therapy; as a result, they were at low risk for rejection which could explain their tolerance of IFNa. However, this hypothesis is not consistent with other studies in which irreversible rejection and return to dialysis occurred in patients treated with IFNa as late as eight years after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are some life-threatening complications of HCV infection in which the benefits of treating outweigh the risk of the possible loss of the renal allograft due to IFNa therapy. Thus, the 2008 KDIGO guidelines for HCV infection in patients with chronic kidney disease recommend that monotherapy with standard IFNa only be considered in kidney transplant recipients with HCV infection resulting in fibrosing cholestatic hepatitis or life-threatening vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/30\">",
"     30",
"    </a>",
"    ]. They also state that the patient should be clearly informed of the risks prior to initiating therapy.",
"   </p>",
"   <p>",
"    The use of pegylated IFNa in renal transplant recipients late after transplantation has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/67\">",
"     67",
"    </a>",
"    ]. Eight renal transplant recipients received treatment with pegylated IFNa after a mean delay between renal transplantation and antiviral treatment of 198.8 months. No patient experienced rejection during or after the treatment. One patient developed hemolytic uremic syndrome, which was complicated by graft loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited efficacy, high cost, increased risk of acute rejection, and significant side effects associated with the use of IFNa have dampened enthusiasm for its use among transplant recipients with chronic HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/68\">",
"     68",
"    </a>",
"    ]. Consistent with this view is the NIH Consensus Statement on management of hepatitis C that currently lists renal transplant as a",
"    <strong>",
"     contraindication",
"    </strong>",
"    to treatment with interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/69\">",
"     69",
"    </a>",
"    ]. We also do not recommend pegylated interferon which, in large randomized trials in patients without renal disease, has produced superior outcomes compared to standard IFNa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are some life-threatening complications of HCV infection in which the benefits of treating may justify the risk of possible loss of the renal allograft with IFNa therapy. The 2008 KDIGO guidelines for HCV infection in patients with chronic kidney disease recommend that monotherapy with standard IFNa only be considered in kidney transplant recipients with HCV infection resulting in fibrosing cholestatic hepatitis or life-threatening vasculitis. They also state that the patient should be clearly informed of the risks prior to initiating therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ribavirin alone after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are less data available on the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    alone in patients who cannot be treated with IFNa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. In two histologic studies, treatment with ribavirin alone was associated with improvement in histologic parameters in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/75\">",
"     75",
"    </a>",
"    ], but not another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/74\">",
"     74",
"    </a>",
"    ]. Possible explanations for this disparity are that, in the study showing improvement, initial histologic injury was more severe, the duration and dose of ribavirin were higher, and the report failed to include a control group. Tolerance to ribavirin varied, with some patients requiring significant amounts of erythropoietin, while the agent had to be discontinued in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Interferon alfa before transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A safer but probably less cost-effective strategy might be to treat chronic hepatitis C in dialysis patients, who are considered transplant candidates, prior to transplantation. IFNa therapy of HCV-infected patients undergoing hemodialysis seems to have a beneficial effect on the course of liver disease following renal transplant, regardless of the virological response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition to high rates of sustained biochemical and virological response with this regimen, neither recurrence of liver disease nor an increased risk of rejection after subsequent transplantation appears to be a major problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/77-83\">",
"     77-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential value of this approach was illustrated in a report of 78 HCV-positive patients who received a renal allograft; 15 had undergone IFNa treatment for one year prior to transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/83\">",
"     83",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 15 patients treated with IFNa, 10 (67 percent) had become HCV-RNA negative by the time of transplantation, and only one (6.7 percent) subsequently developed de novo glomerulonephritis posttransplantation (this patient was HCV-RNA positive at transplantation).",
"     </li>",
"     <li>",
"      In contrast, only 29 percent of the 63 non-interferon-treated allograft recipients were HCV-RNA negative at the time of transplantation, and 12 (19 percent) developed de novo glomerulonephritis (nine with membranoproliferative and three with membranous nephropathy); all 12 were HCV-RNA positive at the time of transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study, the sustained viral response rate among renal transplant candidates treated with pegylated interferon monotherapy was 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/84\">",
"     84",
"    </a>",
"    ]. Four patients with sustained response who were subsequently transplanted did not have recurrence of HCV in the posttransplant period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, data on the relapse rate among renal transplant recipients treated with IFNa for HCV infection prior to transplantation remain limited and controversial. Controlled studies will be required to evaluate the long-term effects of this strategy on the course of liver disease, rates of transplantation, and graft and patient survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2008 KDIGO guidelines for HCV infection in patients with chronic kidney disease that suggest that HCV-infected kidney transplant candidates be considered for treatment with IFNa before transplantation. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31289/abstract/30\">",
"     30",
"    </a>",
"    ]. Details concerning dosing and other issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is impaired in patients with renal failure and ribavirin is not removed by hemodialysis. Similar concerns apply to pegylated interferon because of its long half-life. Thus, ribavirin should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with renal failure and, until data that demonstrate efficacy and safety are available, we do not recommend pegylated interferon in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1524806228\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a high prevalence of hepatitis C virus (HCV) among transplant donors and recipients. The transmission of HCV can result in significant morbidity and mortality of immunosuppressed recipients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatitis c virus and transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The degree to which HCV positive donors who are at risk of transmitting virus are accurately identified depends upon the type of laboratory test that is used. False positive results may result in the unnecessary waste of usable organs. It is not possible to distinguish anti-HCV positive donors with and without serum HCV RNA on the basis of risk factor profiling. We suggest that all anti-HCV positive donors be considered infectious. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence of HCV infection among donors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transplant patients who receive organs from HCV positive donors have higher rates of liver disease but it is not clear whether such patients have lower survival rates than transplant patients who received organs from negative donors. There may be a survival advantage with receiving a kidney from an anti-HCV positive donor versus remaining on a wait-list. However fulminant or subfulminant hepatitis has been reported among patients who received organs from anti-HCV positive donors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical impact of transmission of HCV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCV has several distinct variants. Because HCV does not provide protective immunity, transplant recipients with preexisting HCV infection may develop reinfection with the same or different HCV strain or superinfection if transplanted with a kidney from a HCV infected donor. Limited data suggest that transplantation of kidney from HCV seropositive donors in anti-HCV positive recipients is not associated with adverse post-transplant outcomes in the short term. Using kidneys from HCV seropositive donors for transplantation in anti-HCV positive patients may shorten the waiting time for anti-HCV positive patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Effect of HCV infection upon survival with dialysis or renal transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Transplantation from anti-HCV positive donors into recipients with pretransplantation HCV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several organ procurement organizations and the United States Public Health Service Inter-Agency Guidelines have adopted a policy of testing all cadaver organ donors for anti-HCV and restricting the use of organs from anti-HCV positive donors to life-saving transplants (heart, liver, or lung). However, a better alternative may be a policy of transplanting kidneys from anti-HCV-positive donors to only HCV RNA-positive recipients. This approach is consistent with recommendations from the 2008 KDIGO guidelines. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Policies on the use of organs from donors with HCV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recipients who are anti-HCV positive before transplantation have a significantly increased risk of posttransplant chronic active hepatitis. It is not known whether survival for anti-HCV positive patients is greater with renal replacement therapy with dialysis or with transplantation. We suggest that anti-HCV positive patients",
"      <strong>",
"       without",
"      </strong>",
"      evidence of liver disease on biopsy be allowed to make an informed choice of staying on dialysis or undergoing transplantation. In patients with histological evidence of liver disease, the decision to proceed with renal transplantation should be made cautiously, since immunosuppression may increase viral replication and possibly exacerbate liver disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of pretransplantation anti-HCV status on posttransplantation clinical outcome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Effect of HCV infection upon survival with dialysis or renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment of transplant patients with HCV infection is not known. Interferon alfa (IFNa) may cause allograft rejection in the transplant recipient with HCV. However, there are some life-threatening complications of HCV infection in which the benefits of treating outweigh the risk of the possible loss of the renal allograft due to IFNa therapy. We agree with the 2008 KDIGO guidelines that monotherapy with standard IFNa only be considered in kidney transplant recipients with HCV infection resulting in fibrosing cholestatic hepatitis or life-threatening vasculitis. The patient should be clearly informed of the risks prior to initiating therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It may be safer to treat chronic HCV infection in dialysis patients who are considered transplant candidates before rather than after transplantation. We agree with the 2008 KDIGO guidelines that suggest that HCV-infected kidney transplant candidates be considered for treatment with IFNa before transplantation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clearance of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      is impaired in patients with renal failure and ribavirin is not removed by hemodialysis. Similar concerns apply to pegylated interferon because of its long half-life. We recommend not using ribavirin for patients with renal failure. We recommend not using pegylated interferon for patients with renal failure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/1\">",
"      Pereira BJ. Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant 1995; 10 Suppl 1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/2\">",
"      Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/3\">",
"      LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al. Impact of hepatitis on renal transplantation. Transplantation 1981; 32:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/4\">",
"      Weir MR, Kirkman RL, Strom TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney Int 1985; 28:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/5\">",
"      Rao KV, Anderson WR, Kasiske BL, Dahl DC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/6\">",
"      Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/7\">",
"      Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/8\">",
"      Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/9\">",
"      Pereira BJ, Wright TL, Schmid CH, et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int 1994; 46:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/10\">",
"      Challine D, Pellegrin B, Bouvier-Alias M, et al. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004; 364:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/11\">",
"      Preiksaitis JK, Cockfield SM, Fenton JM, et al. Serologic responses to hepatitis C virus in solid organ transplant recipients. Transplantation 1997; 64:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/12\">",
"      Mendez R, Aswad S, Bogaard T, et al. Donor hepatitis C antibody virus testing in renal transplantation. Transplant Proc 1993; 25:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/13\">",
"      Tesi RJ, Waller MK, Morgan CJ, et al. Use of low-risk HCV-positive donors for kidney transplantation. Transplant Proc 1993; 25:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/14\">",
"      Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/15\">",
"      Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/16\">",
"      Bouthot BA, Murthy BV, Schmid CH, et al. Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement. Transplantation 1997; 63:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/17\">",
"      Mendez, R, El-Shahawy, M, Obispo, E, et al. Four years follow up of hepatitis C positive kidneys into hepatitis C negative recipients &mdash; Prospective study. J Am Soc Nephrol 1995; 6:1105.",
"     </a>",
"    </li>",
"    <li>",
"     Pirsch, JD, Heisey, D, D'Allesandro, AM, et al. Transplantation of hepatitis C (HCV) kidneys: Defining the risks (abstract). 14th Annual Meeting of the American Society of Transplant Physicians, Chicago, May 14-17, 1995, p. 98.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/19\">",
"      Abbott KC, Lentine KL, Bucci JR, et al. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/20\">",
"      Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/21\">",
"      Widell A, M&aring;nsson S, Persson NH, et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60:642.",
"     </a>",
"    </li>",
"    <li>",
"     Oldach, D, Constantine, N, Schweitzer, E, et al. Clinical and virological outcomes in hepatitis C virus (HCV)-infected renal transplant recipients. 14th Annual Meeting of the American Society of Transplant Physicians, Chicago, May 14-17, 1995, p. 98.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/23\">",
"      Natov SN, Lau JY, Ruthazer R, et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1999; 56:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/24\">",
"      Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/25\">",
"      Ali MK, Light JA, Barhyte DY, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998; 66:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/26\">",
"      Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000; 14:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/27\">",
"      Pereira BJ, Milford EL, Kirkman RL, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/28\">",
"      Aeder MI, Shield CF, Tegtmeier GE, et al. Incidence and clinical impact of hepatitis C virus-positive donors in cadaveric transplantation. Transplant Proc 1993; 25:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/29\">",
"      Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/30\">",
"      KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73(Suppl 109):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/31\">",
"      Morales JM, Campistol JM, Andr&eacute;s A, et al. Policies concerning the use of kidneys from donors infected with hepatitis C virus. Nephrol Dial Transplant 2000; 15 Suppl 8:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/32\">",
"      Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant 2002; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/33\">",
"      Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/34\">",
"      Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/35\">",
"      Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C--its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/36\">",
"      Huang CC, Liaw YF, Lai MK, et al. The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 1992; 53:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/37\">",
"      Ponz E, Campistol JM, Barrera JM, et al. Hepatitis C virus antibodies in patients on hemodialysis and after kidney transplantation. Transplant Proc 1991; 23:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/38\">",
"      Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/39\">",
"      Roth D. Hepatitis C virus: the nephrologist's view. Am J Kidney Dis 1995; 25:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/40\">",
"      Ynares, C, Johnson, HK, Kerlin, T, et al. Impact of pretransplant hepatitis C antibody status upon long-term patient and renal allograft survival &mdash; A 5- and 10-year follow-up. Transplantation Proc 1993; 25(1 Pt 2):1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/41\">",
"      Fritsche C, Brandes JC, Delaney SR, et al. Hepatitis C is a poor prognostic indicator in black kidney transplant recipients. Transplantation 1993; 55:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/42\">",
"      Bruchfeld, A, Wilczek, H, Elinder, CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation 2004; 78:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/43\">",
"      Lee SW, Kang SW, Choi KH, et al. Clinical outcome of anti-HCV(+) renal allograft recipients. Transplant Proc 1996; 28:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/44\">",
"      Roth D, Zucker K, Cirocco R, et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/45\">",
"      Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/46\">",
"      Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/47\">",
"      Breitenfeldt MK, Rasenack J, Berthold H, et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/48\">",
"      Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/49\">",
"      Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/50\">",
"      Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/51\">",
"      Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/52\">",
"      Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/53\">",
"      Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/54\">",
"      Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/55\">",
"      Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/56\">",
"      Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol 2005; 3:S113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/57\">",
"      Fabrizi, F, Martin, P. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opin Organ Transplant 2006; 11:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/58\">",
"      Black M, Peters M. Alpha-interferon treatment of chronic hepatitis C: need for accurate diagnosis in selecting patients. Ann Intern Med 1992; 116:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/59\">",
"      Kramer, P, Ten Kate, FJW, Bijnen, AB, et al. The pathology of interferon induced renal allograft lesions. Transplant Proc 1985; 17:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/60\">",
"      Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/61\">",
"      Ozg&uuml;r O, Boyacio��lu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/62\">",
"      Harihara Y, Kurooka Y, Yanagisawa T, et al. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/63\">",
"      Rostaing L, Izopet J, Baron E, et al. Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 1995; 10 Suppl 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/64\">",
"      Chan TM, Lok AS, Cheng IK, Ng IO. Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon. Transplantation 1993; 56:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/65\">",
"      Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3:74.",
"     </a>",
"    </li>",
"    <li>",
"     Rao, KV, Anderson, WR. Clinical and histological outcome following interferon treatment of chronic viral hepatitis, in uremic patients, before and after renal transplantation (abstract). 14th Annual Meeting of the American Society of Transplant Physicians, Chicago, May 14-17, 1995, p. 99.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/67\">",
"      Pageaux GP, Hilleret MN, Garrigues V, et al. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int 2009; 22:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/68\">",
"      Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/69\">",
"      Acupuncture. NIH Consens Statement 1997; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/70\">",
"      Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/71\">",
"      Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/72\">",
"      Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/73\">",
"      Garnier JL, Chevallier P, Dubernard JM, et al. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/74\">",
"      Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/75\">",
"      Fontaine H, Vallet-Pichard A, Equi-Andrade C, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/76\">",
"      Campistol JM, Esforzado N, Mart&iacute;nez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/77\">",
"      Casanovas Taltavull T, Baliellas C, Ses&eacute; E, et al. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc 1995; 27:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/78\">",
"      Duarte R, Huraib S, Said R, et al. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis 1995; 25:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/79\">",
"      Huraib S, Tanimu D, Romeh SA, et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999; 34:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/80\">",
"      Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999; 31:2887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/81\">",
"      Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/82\">",
"      Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/83\">",
"      Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31289/abstract/84\">",
"      Werner T, Aqel B, Balan V, et al. Treatment of hepatitis C in renal transplantation candidates: a single-center experience. Transplantation 2010; 90:407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7361 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31289=[""].join("\n");
var outline_f30_35_31289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1524806228\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATITIS C VIRUS AND TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence of HCV infection among donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transmission of hepatitis C virus infection by organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical impact of transmission of HCV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transplantation from anti-HCV positive donors into recipients with pretransplantation HCV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Policies on the use of organs from donors with HCV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of pretransplantation anti-HCV status on posttransplantation clinical outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effect of HCV genotype on survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect of HCV infection upon survival with dialysis or renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interferon alfa after transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ribavirin alone after transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Interferon alfa before transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1524806228\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29780?source=related_link\">",
"      Characteristics of the hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=related_link\">",
"      Hepatitis C virus infection in patients on maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=related_link\">",
"      Renal disease associated with hepatitis C virus after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_35_31290="Overview of control measures to prevent surgical site infection";
var content_f30_35_31290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of control measures to prevent surgical site infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31290/contributors\">",
"     Deverick J Anderson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31290/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31290/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/35/31290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/35/31290/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/35/31290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical wound infections are the second most common healthcare-associated infection. Although usually localized to the incision site, surgical wound infections can also extend into adjacent deeper structures; thus, the term surgical wound infection has now been replaced with the more suitable name, surgical site infection (SSI).",
"   </p>",
"   <p>",
"    The United States Centers for Disease Control and Prevention (CDC) has developed criteria for defining SSIs, which have become the national standard and are widely used by surveillance and surgical personnel. These criteria define SSIs as infections related to the operative procedure that occur at or near the surgical incision (incisional or",
"    <span class=\"nowrap\">",
"     organ/space)",
"    </span>",
"    within 30 days of an operative procedure or within one year if an implant is left in place. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of and risk factors for surgical site infection\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among surgical patients, SSIs are the most common nosocomial infection, accounting for 38 percent of nosocomial infections. It is estimated that SSIs develop in 2 to 5 percent of the more than 30 million patients undergoing surgical procedures each year (ie, 1 out of every 24 patients who have inpatient surgery in the United States has a postoperative SSI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost of SSIs is substantial. One study found an average total cost of $5155 during the eight-week period after discharge for patients with an SSI diagnosed after discharge, compared with $1773 for those without an SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/3\">",
"     3",
"    </a>",
"    ]. The cost of an SSI due to a resistant organism is likely even higher. In an analysis of 150 patients with SSI due to MRSA, 231 uninfected-matched controls, and 128 patients with SSI due to MSSA, SSI due to MRSA led to more than $60,000 of attributable charges compared with uninfected controls and more than $20,000 compared with patients with SSI due to MSSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Surgical Care Improvement Project (SCIP) is a nationwide initiative to improve surgical care by reducing complications such as infection, heart attack, and blood clots. Hospitals around the country have joined in the SCIP partnership [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General control measures to reduce SSI rates will be reviewed here. Controversies in control measures to reduce SSI rates, and the definition, epidemiology, risk factors, and pathogenesis for these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=see_link\">",
"     \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important factors in the prevention of surgical site infection (SSIs) are meticulous operative techniques and timely administration of effective preoperative antibiotics. A number of interventions have been used over the years to reduce the risk of SSIs, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative showering with antimicrobial soaps",
"     </li>",
"     <li>",
"      Preoperative application of antiseptics to the skin of the patient",
"     </li>",
"     <li>",
"      Washing and gloving of the surgeon's hands",
"     </li>",
"     <li>",
"      Use of sterile drapes",
"     </li>",
"     <li>",
"      Use of gowns and masks by operating room personnel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these interventions were developed to reduce contact with flora from the hands, hair, scalp, nares, and oropharynx of hospital personnel, which were believed to be potential sources of microorganisms causing SSIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Skin antisepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine application of antiseptics to the skin should be performed to reduce the burden of skin flora, although bacteria in hair follicles and sebaceous glands cannot be sterilized by preoperative antiseptic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperative skin cleansing with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    -alcohol is superior to povidone-iodine; in a trial of 849 patients undergoing clean-contaminated surgery, the overall rate of SSI was significantly lower in the chlorhexidine-alcohol group than in the povidone-iodine group (9.5 versus 16 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/8\">",
"     8",
"    </a>",
"    ]. Chlorhexidine-alcohol may be superior to iodine-alcohol because chlorhexidine is not inactivated by blood or serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interventions that do not appear to reduce the likelihood of SSI include skin preparation in concentric circles (rather than horizontal preparation) and use of surgical site markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of bathing with an antiseptic preparation prior to surgery to reduce the risk of SSIs is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. In a meta-analysis of six trials involving 10,007 participants, preoperative bathing with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    conferred no benefit over preoperative bathing with other products for reduction of SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Barrier devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary role for barrier devices (masks, caps, gowns, drapes, and shoe covers) is to protect operating room personnel from exposure to infectious blood or body fluids. Their role in SSI prevention is not supported by rigorous study, but their routine use is universally accepted in hospitals where such equipment is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gloves provide protection of personnel from exposure to infectious blood and body fluids and likely reduce the potential for transmission of bacteria to patients from the hands of surgical personnel. However, there is evidence for bacterial migration from undetected perforation of surgical gloves; the risk depends on the type of surgery performed and the duration of wear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgical hand hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical hand hygiene consists of preoperative cleansing of hands and forearms with an antiseptic agent; this practice is universally accepted. Cleansing with aqueous alcoholic solution may be as effective as traditional hand scrubbing with antiseptic soap for prevention of SSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Either antimicrobial soap or an alcohol-based hand rub may be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/21\">",
"     21",
"    </a>",
"    ]. The recommended duration of scrubbing with alcohol based hand rubs is shorter than with antimicrobial soap (varies by product) and scrub brushes are not required for preoperative hand cleaning by surgical staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that good surgical technique reduces the risk of SSIs. Such practices include gentle traction, effective hemostasis, removal of devitalized tissues, obliteration of dead space, irrigation of tissues with saline to avoid excessive drying, use of fine, non-absorbed monofilament suture material, judicious use of closed suction drains, and wound closure without tension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/23\">",
"     23",
"    </a>",
"    ]. The precise role or proportional benefit of each of these techniques in SSI prevention has not been quantitated or proven by rigorous study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of antimicrobial prophylaxis is to prevent surgical site infection (SSI) by reducing the burden of microorganisms at the surgical site during the operative procedure. Prevention of SSIs consists of antimicrobial prophylaxis together with other measures described in the subsequent sections below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of antibiotic prophylaxis for reducing surgical SSI has been clearly established. Preoperative antibiotics are warranted if there is a high risk of infection or if there high risk of deleterious outcomes should infection develop at the surgical site (such in the setting of immune compromise, cardiac surgery,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    implantation of a foreign device). Patients who receive prophylactic antibiotics within one to two hours before the initial incision have lower rates of SSI than patients who receive antibiotics sooner or later than this window (",
"    <a class=\"graphic graphic_table graphicRef79097 \" href=\"mobipreview.htm?22/46/23275\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Timing of prophylaxis'",
"    </a>",
"    below). Antimicrobial therapy administered in the setting of contaminated wounds is not considered prophylactic; in such cases, a therapeutic course of antimicrobial therapy is warranted.",
"   </p>",
"   <p>",
"    Errors in selection or dose of prophylactic antimicrobials are common. Among 34,133 patients undergoing surgery in centers around the United States, an antimicrobial was administered within one hour before incision to only 56 percent of patients, and antimicrobials were discontinued within 24 hours of surgery in only 41 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/27\">",
"     27",
"    </a>",
"    ]. Initiatives such as the Surgical Care Improvement Project have improved the rates of compliance since these earlier studies were performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following parameters for intravenous (IV) antimicrobial prophylaxis prior to surgery based on guidelines established by the Medical Letter and the Surgical Care Improvement Project are appropriate (",
"    <a class=\"graphic graphic_table graphicRef76499 \" href=\"mobipreview.htm?27/33/28188\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"mobipreview.htm?23/52/24397\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87199 \" href=\"mobipreview.htm?0/45/733\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87200 \" href=\"mobipreview.htm?12/1/12317\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87201 \" href=\"mobipreview.htm?13/19/13628\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87202 \" href=\"mobipreview.htm?15/8/15500\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87203 \" href=\"mobipreview.htm?12/38/12907\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87204 \" href=\"mobipreview.htm?25/4/25676\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87205 \" href=\"mobipreview.htm?26/48/27404\">",
"     table 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87206 \" href=\"mobipreview.htm?34/1/34844\">",
"     table 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24,29\">",
"     24,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      (1 to 2 g IV) is a first generation cephalosporin active against streptococci and methicillin susceptible staphylococci; it is generally appropriate for clean procedures.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"       Cefuroxime",
"      </a>",
"      (1.5 g IV) is a second generation cephalosporin with broader coverage against gram-negative organisms; it may be administered in place of cefazolin for thoracic (cardiac and noncardiac) and orthopedic procedures.",
"     </li>",
"     <li>",
"      For procedures that may involve exposure to bowel anaerobes (including Bacteroides fragilis),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      (1 to 2 g IV) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/55/17269?source=see_link\">",
"       cefotetan",
"      </a>",
"      (second generation cephalosporins) have broader coverage including anaerobic activity than the above agents. However, some gram-negative bacilli such as E. coli have become resistant to cefoxitin; in such circumstances, reasonable alternatives include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV) or monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      (3 g IV).",
"     </li>",
"     <li>",
"      Patients with history of allergy to penicillin manifesting as an uncomplicated or minor skin rash may be treated with cephalosporins; allergic cross-reactions to cephalosporins are infrequent except in patients with severe IgE-mediated reactions to penicillin. If an IgE-mediated reaction against penicillin has occurred in the past, cephalosporins should be avoided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=see_link&amp;anchor=H4#H4\">",
"       \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\", section on 'Cephalosporins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alternatives to cephalosporins include intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 to 900 mg) PLUS an agent with activity against gram-negative bacteria such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/30\">",
"       30",
"      </a>",
"      ]. This is particularly important in patients undergoing colorectal or vascular surgery involving a groin incision.",
"     </li>",
"     <li>",
"      Local resistance patterns should be considered.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      is preferable to cephalosporins in locations where methicillin-resistant Staphylococcus aureus or methicillin-resistant coagulase-negative staphylococci are a frequent cause of surgical site infections and in patients who are known to be colonized with methicillin-resistant S. aureus preoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Role of vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thus far the literature does not support benefit of routine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    use over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    , or ceftizoxime for prevention of SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/30-34\">",
"     30-34",
"    </a>",
"    ], even though guidelines issued by the Surgical Care Improvement Project state that vancomycin is an acceptable antibiotic for surgical prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24\">",
"     24",
"    </a>",
"    ]. In fact, a study of preoperative testing for nasal colonization with methicillin-resistant or methicillin-susceptible S. aureus (MRSA) concluded that preoperative prophylaxis with vancomycin was associated with an",
"    <strong>",
"     increased",
"    </strong>",
"    risk (RR 4.34 95% CI 2.19-8.57) of postoperative SSI in patients who had negative nasal testing for MRSA but not in those who had positive nasal tests for MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for SSI prevention is not warranted, there are some clinical circumstances in which vancomycin use may be appropriate preoperative prophylaxis; these include patients with risk factors for postoperative MRSA infection (such as recent hospitalization, renal disease, or diabetes) who are undergoing cardiac, vascular, and orthopedic procedures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    implantation of prosthetic material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24,36\">",
"     24,36",
"    </a>",
"    ]. A beta-lactam antibiotic (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ) should be added for activity against gram-negative organisms. Alternatives for patients allergic to cephalosporins include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is likely that no single MRSA-specific intervention (such as administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) can optimally prevent SSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/37\">",
"     37",
"    </a>",
"    ]. Rather, a multifactorial approach is likely required and further study of the optimal strategy is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Timing of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy should be administered within 60 minutes prior to the surgery to ensure adequate drug tissue levels at the time of initial incision (or within 120 minutes if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or a fluoroquinolone is used) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24,25,29,38-43\">",
"     24,25,29,38-43",
"    </a>",
"    ]. This practice also reduces the likelihood of antibiotic-associated reactions at the time of induction of anesthesia.",
"   </p>",
"   <p>",
"    This practice is supported by a prospective observational study of 2847 patients undergoing elective clean or clean-contaminated surgery in which the rate of SSI was lower among patients who received antimicrobial prophylaxis within 120 minutes before the incision than those who received prophylaxis more than two hours prior to incision (0.6 percent versus 1.4 to 3.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the 60-minute window for prophylaxis has past, administration of antimicrobial therapy 30 to 60 minutes prior to surgery appears to be more effective than administration immediately before surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Repeat dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For procedures lasting less than four hours, a single repeat dose of intravenous antimicrobials is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ]. For procedures lasting more than four hours or in the setting of major blood loss, repeat dosing is indicated every one to two half-lives of the drug in patients with normal renal function (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    every two to five hours,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    every two to three hours,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    every three to four hours,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"     /sulbactam",
"    </span>",
"    every 2 to 4 hours,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    every 6 to 12 hours,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    every 3 to 6 hours, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    every 6 to 8 hours).",
"   </p>",
"   <p>",
"    The potential value of intraoperative redosing for prolonged surgical procedures was illustrated in a retrospective study of 1548 patients who underwent cardiac surgery lasting more than four hours following preoperative administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ; 30 percent received repeat intraoperative dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/46\">",
"     46",
"    </a>",
"    ]. Among those whose procedure lasted more than 400 minutes, intraoperative redosing significantly reduced the risk of SSI (7.7 versus 16.0 percent; adjusted OR 0.44, 95% CI 0.23-0.86).",
"   </p>",
"   <p>",
"    In general, repeat antimicrobial dosing following wound closure is not necessary and may increase antimicrobial resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29,41,47-50\">",
"     29,41,47-50",
"    </a>",
"    ]. In a systematic review of randomized trials, there was no difference in the rate of SSI with single dose compared with multiple-dose regimens given for less than or more than 24 hours (combined odds ratio 1.04, 95% CI 0.86-1.25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TYPES OF SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery (eg, coronary artery bypass, heart valve replacement) is primarily a clean surgery with the majority of patients having a low preoperative risk of infection (eg, NNIS risk index of 0 or 1). Despite their infrequency, deep",
"    <span class=\"nowrap\">",
"     organ/space",
"    </span>",
"    surgical site infections (SSIs) (eg, mediastinitis and prosthetic valve endocarditis) are catastrophic complications associated with substantial morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. aureus and coagulase-negative staphylococci are the predominant pathogens responsible for SSIs in cardiac surgery. When gram-negative bacilli (eg, Escherichia coli, Klebsiella spp, Enterobacter spp, Proteus spp, and Pseudomonas spp) are responsible for SSIs, contamination of the chest usually occurs during the saphenous vein harvesting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 28 studies concluded that antimicrobial prophylaxis is beneficial in cardiothoracic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/53\">",
"     53",
"    </a>",
"    ]. Several early studies describing failures of first generation cephalosporins in preventing SSIs due to methicillin-sensitive S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] led to the adoption of second generation cephalosporins (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ) as the preferred antimicrobial prophylaxis in many centers. However, subsequent clinical trials showed equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/56,57\">",
"     56,57",
"    </a>",
"    ] or even lower rates of S. aureus SSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/58\">",
"     58",
"    </a>",
"    ] with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    compared with cefuroxime.",
"   </p>",
"   <p>",
"    Because of its greater intrinsic activity against staphylococci, narrower side effect profile and antimicrobial spectrum, and much lower cost,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    is our prophylactic agent of choice as it is in the Medical Letter and Surgical Care Improvement Project [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24,29\">",
"     24,29",
"    </a>",
"    ]. The drugs are given intravenously within 60 minutes before the first incision.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are alternatives if allergy limits the use of a cephalosporin. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antibiotic selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    -collagen sponges does not appear to reduce the 90-day sternal wound infection rate among patients with diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high body mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Intravascular device placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not well studied, antimicrobial prophylaxis is generally used before placement of permanent pacemakers, electrophysiologic devices, ventricular assist devices, ventriculoatrial shunts, and arterial patches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/60\">",
"     60",
"    </a>",
"    ]. The dosing regimens are similar to those used for cardiac surgery (",
"    <a class=\"graphic graphic_table graphicRef76499 \" href=\"mobipreview.htm?27/33/28188\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ]. Antimicrobial prophylaxis for placement of a new pacemaker or replacement of a pulse generator is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=see_link&amp;anchor=H36#H36\">",
"     \"Infections involving cardiac implantable electronic devices\", section on 'Prophylaxis at implantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Noncardiac thoracic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is given routinely in thoracic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ]. The efficacy of this approach was illustrated in a randomized trial of 127 patients undergoing thoracic surgery who were assigned to a single preoperative dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 g) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/61\">",
"     61",
"    </a>",
"    ]. Cefazolin therapy was associated with a significant reduction in wound infection (1.5 versus 14 percent) but not in empyema or pneumonia.",
"   </p>",
"   <p>",
"    The recommended antibiotics are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g IV),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (1.5 g IV), or, in selected patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g [10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    IV) (",
"    <a class=\"graphic graphic_table graphicRef87205 \" href=\"mobipreview.htm?26/48/27404\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ]. As mentioned above, the indications for vancomycin are previous colonization with MRSA, hospitals in which MRSA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coagulase-negative staphylococci are a common cause of postoperative infection, and allergy to penicillins or cephalosporins. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antibiotic selection'",
"    </a>",
"    above.)&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is an alternative to vancomycin in patients with beta-lactam allergy.",
"   </p>",
"   <p>",
"    Data evaluating the efficacy of antimicrobial prophylaxis for tube thoracostomy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2236779\">",
"    <span class=\"h2\">",
"     Gastrointestinal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to gastrointestinal surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=see_link\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other types of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is recommended in patients undergoing a variety of other surgical procedures, two of which are reviewed separately. Issues related to the timing of therapy and repeat dosing are discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Timing of prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Orthopedic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis is warranted for total hip or knee replacement and other orthopedic procedures, such as surgical repair of hip and other closed fractures and internal fixation by nails, plates, screws, or wires (",
"    <a class=\"graphic graphic_table graphicRef87204 \" href=\"mobipreview.htm?25/4/25676\">",
"     table 9",
"    </a>",
"    ). A prospective, randomized trial of 437 patients undergoing diagnostic and operative arthroscopic surgery found only one infection and therefore no benefit from antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28198?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of prosthetic joint infections\", section on 'Before and after joint replacement surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Gynecologic or obstetric surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis is warranted for hysterectomy, surgical abortion, cesarean delivery, and certain other procedures (",
"    <a class=\"graphic graphic_table graphicRef87200 \" href=\"mobipreview.htm?12/1/12317\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=see_link&amp;anchor=H9#H9\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Vascular surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative antimicrobial prophylaxis reduces the incidence of postoperative SSI in patients undergoing reconstructive surgery on the abdominal aorta, arterial surgery on the leg involving a groin incision, and amputation of the lower extremity due to critical limb ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ]. Many also recommend prophylaxis for arterial surgery involving implantation of prosthetic material, such as grafts for vascular access for hemodialysis.",
"   </p>",
"   <p>",
"    The recommended drugs in patients undergoing vascular (arterial) surgery are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    and, for patients with beta-lactam allergy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef87206 \" href=\"mobipreview.htm?34/1/34844\">",
"     table 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63103 \" href=\"mobipreview.htm?33/9/33950\">",
"     table 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Genitourinary surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is warranted before urologic procedures when the urine culture is positive or not obtained or a urinary catheter is in place [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ]. Such patients should be treated to sterilize the urine before surgery or should receive a single preoperative dose of a drug active against the most likely pathogen.",
"   </p>",
"   <p>",
"    Antimicrobial prophylaxis also decreases the incidence of postoperative bacteriuria and sepsis in patients with sterile urine undergoing transurethral prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/63\">",
"     63",
"    </a>",
"    ], before transrectal prostatic biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], and implantation of a prosthesis, such as penile implant or artificial sphincter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16664?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgical treatment of erectile dysfunction\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential efficacy of prophylaxis was illustrated in a meta-analysis of 32 randomized trials in patients undergoing transurethral prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/63\">",
"     63",
"    </a>",
"    ]. Prophylaxis significantly reduced the rates of both postoperative bacteriuria (9 versus 26 percent) and clinical septicemia (0.7 versus 4.4 percent). Effective antibiotics included quinolones, cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and aminoglycosides. The Medical Letter recommends",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg PO or 400 mg IV) or trimethoprim-sulfamethoxazole (1 DS tablet orally) in these settings (",
"    <a class=\"graphic graphic_table graphicRef87199 \" href=\"mobipreview.htm?0/45/733\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No specific recommendations are given for prophylaxis prior to implantation of a penile prosthesis. One randomized controlled trial demonstrated that outcomes and antibiotic tissue concentrations in the corpora cavernosa were similar among patients receiving either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"      cefazolin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"      gentamicin",
"     </a>",
"    </span>",
"    prior to penile prosthesis implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of an indwelling catheter, antimicrobial therapy can be discontinued promptly following the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/67\">",
"     67",
"    </a>",
"    ]. When an indwelling catheter must remain in place following prostatic resection, some advocate continuing antimicrobial therapy until the catheter is removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/68\">",
"     68",
"    </a>",
"    ]. Finally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g IV) should be given prior to open or laparoscopic genitourinary procedures (including percutaneous renal surgery or procedures with entry into the urinary tract) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Neurosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis can reduce the incidence of infection, mostly due to Staphylococcus aureus or S. epidermidis, after craniotomy and spinal surgery, including low-risk procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29,69-72\">",
"     29,69-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy in clean neurosurgical operations was illustrated in a trial in which 846 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or no therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/69\">",
"       69",
"      </a>",
"      ]. The treated group had a significantly lower rate of wound infection (1.0 versus 3.6 percent). All infections that occurred involved gram-positive organisms.",
"     </li>",
"     <li>",
"      Efficacy in spinal surgery was illustrated in a meta-analysis that evaluated six randomized trials involving 843 patients; four of the trials, including the previous trial, were general neurosurgical trials that included patients undergoing spinal surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/71\">",
"       71",
"      </a>",
"      ]. Although no individual trial demonstrated a statistically significant benefit from prophylaxis in patients undergoing spinal surgery, a significant reduction in infection rate was noted in the pooled analysis (2.2 versus 5.9 percent, pooled odds ratio 0.37, 95% CI 0.17-0.78).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended antibiotics are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g IV) or, in selected patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g IV) (",
"    <a class=\"graphic graphic_table graphicRef87202 \" href=\"mobipreview.htm?15/8/15500\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ]. The indications for vancomycin are previous colonization with MRSA, hospitals in which MRSA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coagulase-negative staphylococci are a common cause of postoperative infection, and allergy to penicillins or cephalosporins.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is an alternative to vancomycin in patients with beta-lactam allergy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antibiotic selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Head and neck surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 Medical Letter guidelines recommended antimicrobial prophylaxis for head and neck surgery involving an incision through the oral or pharyngeal mucosa (",
"    <a class=\"graphic graphic_table graphicRef87201 \" href=\"mobipreview.htm?13/19/13628\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Breast surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative antibiotic prophylaxis is warranted to reduce the risk of SSI in patients undergoing surgery for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/73\">",
"     73",
"    </a>",
"    ]. Further study is needed to evaluate the role of prophylactic antibiotics for patients undergoing immediate breast reconstruction; some experts favor prophylaxis for reconstructive procedures that involve placement of prosthetic material, such as synthetic mesh or saline implants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     HAIR REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair removal is commonly performed before many surgical procedures in order to provide the surgeon with a \"clean\" field and to prevent hair from falling into the surgical site. However, most studies have shown an increased risk for surgical site infections (SSIs) in patients undergoing preoperative hair removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/74\">",
"     74",
"    </a>",
"    ]. In one study, the rates of SSI were highest when shaving was performed compared with clipping the hair or use of depilatory creams (5.6 compared with 1.7 and 0.6 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/12\">",
"     12",
"    </a>",
"    ]. In another study, scanning electron micrographs showed that razors caused gross skin cuts, clippers caused less injury, and depilatory agents caused no injury to the skin surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/75\">",
"     75",
"    </a>",
"    ]. The timing of hair removal is also important. The lowest rates of SSI were reported when hair was removed just prior to the surgical incision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies in neurosurgical patients have questioned the need for hair shaving. One study evaluated 1038 cranial procedures without hair removal, and compared the rate of infection with 980 patients whose heads were shaven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/77\">",
"     77",
"    </a>",
"    ]. Patients had their hair washed with shampoo and 4 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    within 24 hours of their operation. In the operating room, the surgical site was scrubbed for 8 to 10 minutes with 4 percent chlorhexidine diluted with water, and then cleansed with 10 percent povidone-iodine solution. Prophylactic antibiotics were administered for three days.",
"   </p>",
"   <p>",
"    The investigators observed 13 postoperative wound infections (1.3 percent), including nine deep (0.9 percent) and four superficial (0.4 percent) infections. There was no significant difference between the rate of infection in patients whose heads were shaven or not (12 of 980 versus 13 of 1038). Two small prospective trials in highly selected, non-emergency cases have also supported not shaving hair in neurosurgical operations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis that examined 11 randomized controlled trials concluded that there was no difference in rate of SSIs among patients who have had hair removed prior to surgery and those who have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/80\">",
"     80",
"    </a>",
"    ]. If hair needs to be removed, patients should be clipped rather than shaved, as patients who were shaved were more likely to develop SSI (three trials, 3193 patients, relative risk 2.02, 95% CI, 1.21-3.36).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     S. AUREUS DECOLONIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal carriage of S. aureus is a risk factor for surgical site infection (SSI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/81\">",
"     81",
"    </a>",
"    ]. In regions with high MRSA prevalence, the efficacy of S. aureus decolonization is uncertain, and nares screening may miss as many as 20 percent of patients with S. aureus colonization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Nasopharyngeal decontamination may be effective for reducing the risk of postoperative infection in some situations. Agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    nasal ointment and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    soap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/84-94\">",
"     84-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For circumstances in which the presence of nasal S. aureus carriage can be assessed via rapid screening, decolonization with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    nasal ointment and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    soap may reduce the risk of hospital-associated S. aureus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/95\">",
"     95",
"    </a>",
"    ]. This was illustrated in a trial of 6771 patients undergoing surgery with anticipated hospital stay &ge;4 days who were screened on admission for S. aureus with a real-time polymerase-chain-reaction (PCR) assay; 1251 patients were positive for S. aureus and all strains were susceptible to methicillin and mupirocin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/95\">",
"     95",
"    </a>",
"    ]. Of these, 918 patients were randomized to receive either placebo or decolonization with intranasal mupirocin twice a day for 5 days and daily baths with chlorhexidine soap. The intervention reduced the rate of S. aureus infection from 7.7 to 3.4 percent (relative risk 0.42; 95 percent confidence interval [CI] 0.23 to 0.75).",
"   </p>",
"   <p>",
"    In the accompanying editorial it was suggested that S. aureus decolonization with intranasal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    baths may be appropriate for surgical patients known to be nasal carriers of S. aureus with a high risk of deleterious outcomes should S. aureus infection develop at the surgical site. This includes patients who are immunocompromised, undergoing cardiac surgery,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    undergoing implantation of a foreign device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/96\">",
"     96",
"    </a>",
"    ]. There is no role for routine decolonization.",
"   </p>",
"   <p>",
"    Both high-level and low-level",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    resistance have been associated with decolonization failure. In a case control study of 150 patients, carriage of MRSA with low-level mupirocin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    resistance was independently associated with persistent carriage of MRSA after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of decontamination to eradicate MRSA carriage in hospitals where MRSA is a frequent cause of surgical site infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREOPERATIVE INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with evidence of active infection prior to elective surgical procedures should complete treatment for the infection prior to surgery, particularly in circumstances when placement of prosthetic material is anticipated. For circumstances in which urgent surgery is required, the risk of infection must be weighed with the timing of surgical intervention on an individualized basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     GLUCOSE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia and diabetes have been identified as risk factors for deep sternal site infection after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies have suggested that a preoperative blood glucose level of 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or more (odds ratio [OR] 10.2) or postoperative hyperglycemia (OR, 2.0) is associated with an increased risk of SSIs.",
"   </p>",
"   <p>",
"    A historic cohort study of 1574 patients who had undergone coronary artery bypass grafting between 1998 and 1999 demonstrated that each 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    blood glucose increase may be associated with higher mortality (OR 1.37; 95% CI, 0.98-1.92) and higher infection rate (OR 1.23, 95% CI 0.94-1.60). Each 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    blood glucose increase was associated with a longer postoperative hospital stay by 0.76 days (95% CI, 0.36-1.17 days) and increased hospitalization cost by $1769 (95% CI, $928-$2610) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study of 2467 consecutive diabetic patients who underwent open heart surgical procedures between 1987 and 1997 demonstrated that continuous intravenous insulin infusion led to a significant reduction in perioperative blood glucose levels and incidence of deep sternal wound compared with subcutaneous insulin injections (0.8 versus 2.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further prospective controlled trials are needed to validate the benefits of intensive glucose control on the incidence of SSIs in the perioperative period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE NORMOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild perioperative hypothermia may promote surgical site infection (SSI) by triggering thermoregulatory vasoconstriction that, in turn, may decrease subcutaneous oxygen tension. One study randomized 200 patients undergoing colorectal surgery to routine intraoperative thermal care (the hypothermia group) or additional warming (the normothermia group) and found a lower rate of SSI in the latter group (19 versus 6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar randomized trial comparing systemic normothermia to conventional hypothermia was done in 1732 patients undergoing isolated coronary bypass surgery demonstrated no difference in the rates of sternal",
"    <span class=\"nowrap\">",
"     rewiring/debridement",
"    </span>",
"    for dehiscence or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, hypothermia may protect tissue from ischemia by reducing oxygen consumption during surgery, an effect exploited during circulatory arrest in cardiac surgery. Despite this positive effect, most surgeons, anesthesiologists, and hospital epidemiologists acknowledge the benefit of perioperative normothermia in reducing the risk of SSI.",
"   </p>",
"   <p>",
"    A similar advantage to perioperative warming has been shown in one study of clean surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/104\">",
"     104",
"    </a>",
"    ]. Wound infection was significantly more common among patients who were not warmed before surgery (14 versus 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2237735\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL OXYGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen is important for wound healing, including collagen deposition and proper immune function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/105-109\">",
"     105-109",
"    </a>",
"    ]. Superoxide production, the primary leukocyte bacterial killing method in wounds, is proportional to the amount of oxygen present in the tissue. Tissue hypoxia is a risk factor for wound infection and dehiscence. In addition, tissue hypoxia is probably the primary reason that cigarette smoking is associated with increased risk of surgical site infection (SSI). [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In theory, based on these observations, the use of supplemental oxygen therapy might be expected to reduce the risk of SSI by increasing oxygen pressure in surgical wound tissue. Several randomized controlled trials compared high inspired oxygen fraction (FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 80 percent) to &ldquo;standard care&rdquo; (an FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 30 percent) in surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/111-116\">",
"     111-116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies demonstrated that patients who received FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 80 percent had lower rates of SSI than patients who received FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/111,113-115\">",
"     111,113-115",
"    </a>",
"    ], one study demonstrated that patients who received a FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 80 percent had higher rates of SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/112\">",
"     112",
"    </a>",
"    ], and one study showed no difference between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/116\">",
"     116",
"    </a>",
"    ]. A meta-analysis of five trials concluded that the weight of available evidence favors the use of high inspired oxygen, in spite of insufficient control for antimicrobial prophylaxis and significant heterogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/117\">",
"     117",
"    </a>",
"    ]. It was calculated that the use of high inspired oxygen perioperatively led to a 25 percent relative risk (RR) reduction (RR = 0.74; 95% CI 0.60-0.92).",
"   </p>",
"   <p>",
"    Subsequently, a randomized controlled trial of 1400 patients randomized to receive FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 80 or 30 percent concluded that high inspired oxygen was not associated with lower rates of SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/116\">",
"     116",
"    </a>",
"    ]. In fact, rates of SSI were high in both groups (approximately 20 percent). There were also no differences in frequency of respiratory adverse events, such as atelectasis, pneumonia, respiratory failure, or other complications in the two treatment groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AND INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective infection control program is an essential part of surgical site infection (SSI) prevention. The SENIC study reported that an effective infection prevention program reduced the rate of SSIs by 41 percent in low risk patients and by 35 percent in high risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. In addition, active surveillance and reporting of rates of SSIs to individual surgeons consistently resulted in a progressive decline in infection rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/120,121\">",
"     120,121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, SSI rates should be presented to surgeons and the chief of staff at regular intervals. These rates should be reported as surgeon-specific, service-specific, and hospital-wide and categorized within discrete risk index scores. Precautions need to be taken to ensure the confidentiality of these results. How such feedback brings about changes in surgeons' behavior is not known, but the benefits of its use are well supported.",
"   </p>",
"   <p>",
"    With the increased popularity of same day and ambulatory surgical procedures, the ability to identify and monitor rates for all types of SSI has decreased. This was illustrated in a study of postdischarge surveillance in 1324 patients undergoing CABG over a 27-month period; 88 SSIs were identified, only 28 percent of which would have been detected during the initial hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efforts to track these infections have included patient and surgeon questionnaires and nurse observation of the wounds at the patient's home or during a routine postoperative visit. One report identified SSIs from an automated pharmacy system combined with computerized patient data; this methodology detected 96 SSIs in 4086 operations (2.3 percent) for an overall sensitivity of 74 percent, specificity of 98 percent, and positive predictive value of 48 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/123\">",
"     123",
"    </a>",
"    ]. This performance was superior to patient or physician surveys.",
"   </p>",
"   <p>",
"    A second study directly compared this type of surveillance with hospital-based surveillance in determining SSIs in patients who had undergone CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/124\">",
"     124",
"    </a>",
"    ]. Health plan and automated pharmacy information detected more patients with SSI than hospital surveillance including predischarge infections. One or both methods identified 167 infected patients; the sensitivity of surveillance based upon health plan data was 72 percent compared with 50 percent for hospital surveillance.",
"   </p>",
"   <p>",
"    A prospective cohort study from a tertiary hospital in Spain utilized telephone follow-up one month after surgery to successfully contact 98 percent of 1506 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/125\">",
"     125",
"    </a>",
"    ]. The investigators suggested that predictors of SSI were not the same for patients in the immediate postoperative period while still hospitalized and for those who developed infection following discharge. The only predictors of a postdischarge SSI were body mass index, age, and improperly timed prophylactic antibiotics.",
"   </p>",
"   <p>",
"    The diagnosis of a superficial incisional SSI has a lower sensitivity than the diagnosis of a complex (ie, non-superficial-incisional) SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/126\">",
"     126",
"    </a>",
"    ]. Most superficial incisional SSIs are diagnosed after hospital discharge and rarely require rehospitalization. In contrast, complex SSIs routinely result in rehospitalization and additional surgery. In addition, no specific recommendations are available regarding the best method for postdischarge surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/110\">",
"     110",
"    </a>",
"    ]. In fact, a systematic review of methods for postdischarge surveillance concluded that existing research has not identified a valid and reliable method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood that superficial incisional SSIs will be reported is highly dependent on the systems that hospitals use to perform surveillance. Thus, interhospital comparisons of rates of SSI are not likely to be meaningful to surgeons if the surveillance systems for these SSIs are not consistent. Hospitals that perform rigorous postdischarge surveillance will inevitably find higher numbers of SSIs than hospitals that do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/128\">",
"     128",
"    </a>",
"    ]. For example, the rates of SSI in The Netherlands were much higher than the rates of SSI in Germany when all the SSIs were evaluated; this difference was minimal, however, when only complex SSIs were analyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of all of the above considerations, we recommended that surveillance for SSIs be limited to \"complex\" (ie, nonsuperficial incisional) SSIs diagnosed in inpatient settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/130\">",
"     130",
"    </a>",
"    ]. Our review of more than 180,000 surgical patients and 2257 SSIs demonstrated that the NHSN Risk Index could be used to risk-stratify \"complex\" SSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     INSTITUTE FOR HEALTHCARE IMPROVEMENT CAMPAIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Institute for Healthcare Improvement (IHI) initiated the 100,000 Lives Campaign to engage United States hospitals in a commitment to implement changes proven to improve patient care and prevent avoidable deaths. The initiatives in this campaign were included in the newer 5 Million Lives Campaign along with specific recommendations to reduce the incidence of surgical site infections by promoting the following modalities, which were adopted earlier by the Surgical Infection Prevention and Surgical Care Improvement Projects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24\">",
"     24",
"    </a>",
"    ] (",
"    <a class=\"external\" href=\"file://www.ihi.org/IHI/Programs/Campaign/\">",
"     www.ihi.org/IHI/Programs/Campaign/",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate use of antibiotics &mdash; Antibiotics should be administered within one hour before surgical incision, the choice of prophylactic antibiotics should be consistent with national guidelines, and prophylactic antibiotics should be discontinued within 24 hours after surgery.",
"     </li>",
"     <li>",
"      Appropriate hair removal &mdash; Remove all razors from entire hospital, work with purchasing department so that razors are no longer purchased, use reminders, and educate patients not to self-shave preoperatively.",
"     </li>",
"     <li>",
"      Maintenance of postoperative glucose control for major cardiac surgery patients &mdash; Implement a glucose control protocol, regularly check preoperative glucose levels on all patients, and assign responsibility and accountability for blood glucose monitoring and control.",
"     </li>",
"     <li>",
"      Establishment of perioperative normothermia &mdash; Use warmed, forced-air blankets preoperatively during surgery and in the Post Anesthesia Care Unit (PACU), use warmed IV fluids, increase the ambient temperature in the operating room, use warming blankets under patients on the operating table, and use hats and booties on patients preoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospitals that collaborated by instituting programs to utilize the above four measures reported a mean 27 percent reduction in SSI rates (from 2.3 to 1.7 percent in the first versus last three months of the study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/28\">",
"     28",
"    </a>",
"    ]. A review of data from multiple centers including more than 400,000 patients noted that patients who received at least two of the above measures had lower rates of SSI (adjusted OR 0.85, 95% CI 0.74-0.95) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/35/31290/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/1\">",
"      Consensus paper on the surveillance of surgical wound infections. The Society for Hospital Epidemiology of America; The Association for Practitioners in Infection Control; The Centers for Disease Control; The Surgical Infection Society. Infect Control Hosp Epidemiol 1992; 13:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/2\">",
"      Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/3\">",
"      Perencevich EN, Sands KE, Cosgrove SE, et al. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003; 9:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/4\">",
"      Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One 2009; 4:e8305.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.jointcommission.org/surgical_care_improvement_project/ (Accessed on November 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/6\">",
"      Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/7\">",
"      Selwyn S, Ellis H. Skin bacteria and skin disinfection reconsidered. Br Med J 1972; 1:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/8\">",
"      Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med 2010; 362:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/9\">",
"      Brown TR, Ehrlich CE, Stehman FB, et al. A clinical evaluation of chlorhexidine gluconate spray as compared with iodophor scrub for preoperative skin preparation. Surg Gynecol Obstet 1984; 158:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/10\">",
"      Stonecypher K. Going around in circles: is this the best practice for preparing the skin? Crit Care Nurs Q 2009; 32:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/11\">",
"      Zhao X, Chen J, Fang XQ, Fan SW. Surgical site marking will not affect sterility of the surgical field. Med Hypotheses 2009; 73:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/12\">",
"      Cruse PJ, Foord R. The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds. Surg Clin North Am 1980; 60:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/13\">",
"      Hayek LJ, Emerson JM, Gardner AM. A placebo-controlled trial of the effect of two preoperative baths or showers with chlorhexidine detergent on postoperative wound infection rates. J Hosp Infect 1987; 10:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/14\">",
"      Rotter ML, Hirschl AM, Koller W. Effect of chlorhexidine-containing detergent, non-medicated soap or isopropanol and the influence of neutralizer on bacterial pathogenicity. J Hosp Infect 1988; 11:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/15\">",
"      Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev 2006; :CD004985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/16\">",
"      Belkin NL. The evolution of the surgical mask: filtering efficiency versus effectiveness. Infect Control Hosp Epidemiol 1997; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/17\">",
"      Brough SJ, Hunt TM, Barrie WW. Surgical glove perforations. Br J Surg 1988; 75:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/18\">",
"      H&uuml;bner NO, Goerdt AM, Stanislawski N, et al. Bacterial migration through punctured surgical gloves under real surgical conditions. BMC Infect Dis 2010; 10:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/19\">",
"      Tanner J, Swarbrook S, Stuart J. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev 2008; :CD004288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/20\">",
"      Parienti JJ, Thibon P, Heller R, et al. Hand-rubbing with an aqueous alcoholic solution vs traditional surgical hand-scrubbing and 30-day surgical site infection rates: a randomized equivalence study. JAMA 2002; 288:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/21\">",
"      Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002; 23:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/22\">",
"      Tanner J. Surgical hand antisepsis: the evidence. J Perioper Pract 2008; 18:330.",
"     </a>",
"    </li>",
"    <li>",
"     Altemeier WA, Burke JF, Pruitt BA, Sandusky WR. Manual on Control of Infection in Surgical Patients, JB Lippincott, Philadelphia 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/24\">",
"      Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006; 43:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/25\">",
"      Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/26\">",
"      van Kasteren ME, Manni&euml;n J, Ott A, et al. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis 2007; 44:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/27\">",
"      Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005; 140:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/28\">",
"      Dellinger EP, Hausmann SM, Bratzler DW, et al. Hospitals collaborate to decrease surgical site infections. Am J Surg 2005; 190:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/29\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2009; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/30\">",
"      Bolon MK, Morlote M, Weber SG, et al. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis 2004; 38:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/31\">",
"      Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002; 123:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/32\">",
"      Vuorisalo S, Pokela R, Syrj&auml;l&auml; H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1998; 19:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/33\">",
"      Pons VG, Denlinger SL, Guglielmo BJ, et al. Ceftizoxime versus vancomycin and gentamicin in neurosurgical prophylaxis: a randomized, prospective, blinded clinical study. Neurosurgery 1993; 33:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/34\">",
"      Crawford T, Rodvold KA, Solomkin JS. Vancomycin for surgical prophylaxis? Clin Infect Dis 2012; 54:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/35\">",
"      Gupta K, Strymish J, Abi-Haidar Y, et al. Preoperative nasal methicillin-resistant Staphylococcus aureus status, surgical prophylaxis, and risk-adjusted postoperative outcomes in veterans. Infect Control Hosp Epidemiol 2011; 32:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/36\">",
"      Garey KW, Lai D, Dao-Tran TK, et al. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother 2008; 52:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/37\">",
"      Awad SS, Palacio CH, Subramanian A, et al. Implementation of a methicillin-resistant Staphylococcus aureus (MRSA) prevention bundle results in decreased MRSA surgical site infections. Am J Surg 2009; 198:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/38\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/39\">",
"      Dellinger EP. Prophylactic antibiotics: administration and timing before operation are more important than administration after operation. Clin Infect Dis 2007; 44:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/40\">",
"      Zelenitsky SA, Ariano RE, Harding GK, Silverman RE. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. Antimicrob Agents Chemother 2002; 46:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/41\">",
"      Goldmann DA, Hopkins CC, Karchmer AW, et al. Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg 1977; 73:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/42\">",
"      DiPiro JT, Vallner JJ, Bowden TA Jr, et al. Intraoperative serum and tissue activity of cefazolin and cefoxitin. Arch Surg 1985; 120:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/43\">",
"      Wong-Beringer A, Corelli RL, Schrock TR, Guglielmo BJ. Influence of timing of antibiotic administration on tissue concentrations during surgery. Am J Surg 1995; 169:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/44\">",
"      Weber WP, Marti WR, Zwahlen M, et al. The timing of surgical antimicrobial prophylaxis. Ann Surg 2008; 247:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/45\">",
"      Garey KW, Dao T, Chen H, et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother 2006; 58:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/46\">",
"      Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis 2001; 7:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/47\">",
"      McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Aust N Z J Surg 1998; 68:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/48\">",
"      Conte JE Jr, Cohen SN, Roe BB, Elashoff RM. Antibiotic prophylaxis and cardiac surgery. A prospective double-blind comparison of single-dose versus multiple-dose regimens. Ann Intern Med 1972; 76:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/49\">",
"      Pollard JP, Hughes SP, Scott JE, et al. Antibiotic prophylaxis in total hip replacement. Br Med J 1979; 1:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/50\">",
"      Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000; 101:2916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/51\">",
"      Wells FC, Newsom SW, Rowlands C. Wound infection in cardiothoracic surgery. Lancet 1983; 1:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/52\">",
"      Farrington M, Webster M, Fenn A, Phillips I. Study of cardiothoracic wound infection at St. Thomas' Hospital. Br J Surg 1985; 72:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/53\">",
"      Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992; 104:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/54\">",
"      Kaiser AB, Petracek MR, Lea JW 4th, et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double-blind trial in 1030 patients. Ann Surg 1987; 206:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/55\">",
"      Kernodle DS, Classen DC, Burke JP, Kaiser AB. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections. JAMA 1990; 263:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/56\">",
"      Curtis JJ, Boley TM, Walls JT, et al. Randomized, prospective comparison of first- and second-generation cephalosporins as infection prophylaxis for cardiac surgery. Am J Surg 1993; 166:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/57\">",
"      Townsend TR, Reitz BA, Bilker WB, Bartlett JG. Clinical trial of cefamandole, cefazolin, and cefuroxime for antibiotic prophylaxis in cardiac operations. J Thorac Cardiovasc Surg 1993; 106:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/58\">",
"      Doebbeling BN, Pfaller MA, Kuhns KR, et al. Cardiovascular surgery prophylaxis. A randomized, controlled comparison of cefazolin and cefuroxime. J Thorac Cardiovasc Surg 1990; 99:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/59\">",
"      Bennett-Guerrero E, Ferguson TB Jr, Lin M, et al. Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA 2010; 304:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/60\">",
"      Baddour LM, Bettmann MA, Bolger AF, et al. Nonvalvular cardiovascular device-related infections. Circulation 2003; 108:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/61\">",
"      Aznar R, Mateu M, Mir&oacute; JM, et al. Antibiotic prophylaxis in non-cardiac thoracic surgery: cefazolin versus placebo. Eur J Cardiothorac Surg 1991; 5:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/62\">",
"      Wieck JA, Jackson JK, O'Brien TJ, et al. Efficacy of prophylactic antibiotics in arthroscopic surgery. Orthopedics 1997; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/63\">",
"      Berry A, Barratt A. Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis. J Urol 2002; 167:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/64\">",
"      Kapoor DA, Klimberg IW, Malek GH, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998; 52:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/65\">",
"      Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/66\">",
"      Schwartz BF, Swanzy S, Thrasher JB. A randomized prospective comparison of antibiotic tissue levels in the corpora cavernosa of patients undergoing penile prosthesis implantation using gentamicin plus cefazolin versus an oral fluoroquinolone for prophylaxis. J Urol 1996; 156:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/67\">",
"      Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40:643.",
"     </a>",
"    </li>",
"    <li>",
"     J Antimicrob Chemother 1982; 138:245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/69\">",
"      Young RF, Lawner PM. Perioperative antibiotic prophylaxis for prevention of postoperative neurosurgical infections. A randomized clinical trial. J Neurosurg 1987; 66:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/70\">",
"      Korinek AM, Baugnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2006; 59:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/71\">",
"      Barker FG 2nd. Efficacy of prophylactic antibiotic therapy in spinal surgery: a meta-analysis. Neurosurgery 2002; 51:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/72\">",
"      Dimick JB, Lipsett PA, Kostuik JP. Spine update: antimicrobial prophylaxis in spine surgery: basic principles and recent advances. Spine (Phila Pa 1976) 2000; 25:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/73\">",
"      Bunn F, Jones DJ, Bell-Syer S. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev 2012; 1:CD005360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/74\">",
"      Mishriki SF, Law DJ, Jeffery PJ. Factors affecting the incidence of postoperative wound infection. J Hosp Infect 1990; 16:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/75\">",
"      Hamilton HW, Hamilton KR, Lone FJ. Preoperative hair removal. Can J Surg 1977; 20:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/76\">",
"      Seropian R, Reynolds BM. Wound infections after preoperative depilatory versus razor preparation. Am J Surg 1971; 121:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/77\">",
"      Bekar A, Korfali E, Do��an S, et al. The effect of hair on infection after cranial surgery. Acta Neurochir (Wien) 2001; 143:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/78\">",
"      Tang K, Yeh JS, Sgouros S. The Influence of hair shave on the infection rate in neurosurgery. A prospective study. Pediatr Neurosurg 2001; 35:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/79\">",
"      Ratanalert S, Saehaeng S, Sripairojkul B, et al. Nonshaved cranial neurosurgery. Surg Neurol 1999; 51:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/80\">",
"      Tanner J, Woodings D, Moncaster K. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev 2006; :CD004122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/81\">",
"      Kluytmans JA, Mouton JW, Ijzerman EP, et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995; 171:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/82\">",
"      Anderson DJ, Sexton DJ, Kanafani ZA, et al. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/83\">",
"      Coello R, Jim&eacute;nez J, Garc&iacute;a M, et al. Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients. Eur J Clin Microbiol Infect Dis 1994; 13:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/84\">",
"      Segers P, Speekenbrink RG, Ubbink DT, et al. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 2006; 296:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/85\">",
"      Doebbeling BN, Reagan DR, Pfaller MA, et al. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994; 154:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/86\">",
"      van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008; :CD006216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/87\">",
"      Kluytmans JA, Mouton JW, VandenBergh MF, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996; 17:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/88\">",
"      Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal AM, Edixhoven PJ, Spies-van Rooijen NH. Prophylactic mupirocin could reduce orthopedic wound infections. 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand 1998; 69:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/89\">",
"      Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002; 346:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/90\">",
"      Farr BM. Mupirocin to prevent S. aureus infections. N Engl J Med 2002; 346:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/91\">",
"      Suzuki Y, Kamigaki T, Fujino Y, et al. Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery. Br J Surg 2003; 90:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/92\">",
"      Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 2002; 35:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/93\">",
"      Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol 2005; 26:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/94\">",
"      Shrestha NK, Banbury MK, Weber M, et al. Safety of targeted perioperative mupirocin treatment for preventing infections after cardiac surgery. Ann Thorac Surg 2006; 81:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/95\">",
"      Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/96\">",
"      Wenzel RP. Minimizing surgical-site infections. N Engl J Med 2010; 362:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/97\">",
"      Lee AS, Macedo-Vinas M, Fran&ccedil;ois P, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011; 52:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/98\">",
"      Trick WE, Scheckler WE, Tokars JI, et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/99\">",
"      Latham R, Lancaster AD, Covington JF, et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001; 22:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/100\">",
"      Estrada CA, Young JA, Nifong LW, Chitwood WR Jr. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg 2003; 75:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/101\">",
"      Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/102\">",
"      Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/103\">",
"      Randomised trial of normothermic versus hypothermic coronary bypass surgery. The Warm Heart Investigators. Lancet 1994; 343:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/104\">",
"      Melling AC, Ali B, Scott EM, Leaper DJ. Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomised controlled trial. Lancet 2001; 358:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/105\">",
"      Allen DB, Maguire JJ, Mahdavian M, et al. Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. Arch Surg 1997; 132:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/106\">",
"      Hopf HW, Hunt TK, West JM, et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg 1997; 132:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/107\">",
"      Hunt TK, Linsey M, Grislis H, et al. The effect of differing ambient oxygen tensions on wound infection. Ann Surg 1975; 181:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/108\">",
"      Hartmann M, J&ouml;nsson K, Zederfeldt B. Effect of tissue perfusion and oxygenation on accumulation of collagen in healing wounds. Randomized study in patients after major abdominal operations. Eur J Surg 1992; 158:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/109\">",
"      Kohanski MA, Dwyer DJ, Hayete B, et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/110\">",
"      Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/111\">",
"      Greif R, Ak&ccedil;a O, Horn EP, et al. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med 2000; 342:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/112\">",
"      Pryor KO, Fahey TJ 3rd, Lien CA, Goldstein PA. Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: a randomized controlled trial. JAMA 2004; 291:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/113\">",
"      Belda FJ, Aguilera L, Garc&iacute;a de la Asunci&oacute;n J, et al. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. JAMA 2005; 294:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/114\">",
"      Mayzler O, Weksler N, Domchik S, et al. Does supplemental perioperative oxygen administration reduce the incidence of wound infection in elective colorectal surgery? Minerva Anestesiol 2005; 71:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/115\">",
"      Myles PS, Leslie K, Chan MT, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology 2007; 107:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/116\">",
"      Meyhoff CS, Wetterslev J, Jorgensen LN, et al. Effect of high perioperative oxygen fraction on surgical site infection and pulmonary complications after abdominal surgery: the PROXI randomized clinical trial. JAMA 2009; 302:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/117\">",
"      Qadan M, Ak&ccedil;a O, Mahid SS, et al. Perioperative supplemental oxygen therapy and surgical site infection: a meta-analysis of randomized controlled trials. Arch Surg 2009; 144:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/118\">",
"      Haley RW, Quade D, Freeman HE, Bennett JV. The SENIC Project. Study on the efficacy of nosocomial infection control (SENIC Project). Summary of study design. Am J Epidemiol 1980; 111:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/119\">",
"      Haley RW, Culver DH, White JW, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 1985; 121:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/120\">",
"      Condon RE, Schulte WJ, Malangoni MA, Anderson-Teschendorf MJ. Effectiveness of a surgical wound surveillance program. Arch Surg 1983; 118:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/121\">",
"      Olson MM, Lee JT Jr. Continuous, 10-year wound infection surveillance. Results, advantages, and unanswered questions. Arch Surg 1990; 125:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/122\">",
"      Avato JL, Lai KK. Impact of postdischarge surveillance on surgical-site infection rates for coronary artery bypass procedures. Infect Control Hosp Epidemiol 2002; 23:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/123\">",
"      Sands K, Vineyard G, Livingston J, et al. Efficient identification of postdischarge surgical site infections: use of automated pharmacy dispensing information, administrative data, and medical record information. J Infect Dis 1999; 179:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/124\">",
"      Sands KE, Yokoe DS, Hooper DC, et al. Detection of postoperative surgical-site infections: comparison of health plan-based surveillance with hospital-based programs. Infect Control Hosp Epidemiol 2003; 24:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/125\">",
"      Delgado-Rodr&iacute;guez M, G&oacute;mez-Ortega A, Sillero-Arenas M, Llorca J. Epidemiology of surgical-site infections diagnosed after hospital discharge: a prospective cohort study. Infect Control Hosp Epidemiol 2001; 22:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/126\">",
"      Yokoe DS, Noskin GA, Cunnigham SM, et al. Enhanced identification of postoperative infections among inpatients. Emerg Infect Dis 2004; 10:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/127\">",
"      Petherick ES, Dalton JE, Moore PJ, Cullum N. Methods for identifying surgical wound infection after discharge from hospital: a systematic review. BMC Infect Dis 2006; 6:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/128\">",
"      Barnes S, Salemi C, Fithian D, et al. An enhanced benchmark for prosthetic joint replacement infection rates. Am J Infect Control 2006; 34:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/129\">",
"      Manni&euml;n J, van den Hof S, Brandt C, et al. Comparison of the National Surgical Site Infection surveillance data between The Netherlands and Germany: PREZIES versus KISS. J Hosp Infect 2007; 66:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/130\">",
"      Anderson DJ, Chen LF, Sexton DJ, Kaye KS. Complex surgical site infections and the devilish details of risk adjustment: important implications for public reporting. Infect Control Hosp Epidemiol 2008; 29:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/35/31290/abstract/131\">",
"      Stulberg JJ, Delaney CP, Neuhauser DV, et al. Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA 2010; 303:2479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4043 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31290=[""].join("\n");
var outline_f30_35_31290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Skin antisepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Barrier devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgical hand hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANTIMICROBIAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Role of vancomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Timing of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Repeat dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TYPES OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Intravascular device placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Noncardiac thoracic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2236779\">",
"      Gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other types of surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Orthopedic surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Gynecologic or obstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Vascular surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Genitourinary surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Neurosurgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Head and neck surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Breast surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      HAIR REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      S. AUREUS DECOLONIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREOPERATIVE INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GLUCOSE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PERIOPERATIVE NORMOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2237735\">",
"      SUPPLEMENTAL OXYGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SURVEILLANCE AND INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      INSTITUTE FOR HEALTHCARE IMPROVEMENT CAMPAIGNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/4043\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/4043|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/46/23275\" title=\"table 1\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/33/28188\" title=\"table 2\">",
"      Antimicrobial prophylaxis for cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/52/24397\" title=\"table 3\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/45/733\" title=\"table 4\">",
"      Antimicrobial prophylaxis for genitourinary surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/1/12317\" title=\"table 5\">",
"      Antimicrobial prophylaxis for gynecologic and obstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/19/13628\" title=\"table 6\">",
"      Antimicrobial prophylaxis for head and neck surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/8/15500\" title=\"table 7\">",
"      Antimicrobial prophylaxis for neurosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/38/12907\" title=\"table 8\">",
"      Antimicrobial prophylaxis for ophthalmic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/4/25676\" title=\"table 9\">",
"      Antimicrobial prophylaxis for orthopedic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/48/27404\" title=\"table 10\">",
"      Antimicrobial prophylaxis for thoracic non-cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/1/34844\" title=\"table 11\">",
"      Antimicrobial prophylaxis for vascular surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/9/33950\" title=\"table 12\">",
"      Prophylaxis recommendations for vascular and IR procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16664?source=related_link\">",
"      Surgical treatment of erectile dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_35_31291="Ideal menstrual frequency poll";
var content_f30_35_31291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dutch women's view of ideal menstruation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Age of women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        15-19 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        20-24 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        25-34 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"3\" rowspan=\"1\">",
"        Percent who prefer the specified menstrual frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once a month",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once every 3 months",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once every 6 months",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once a year",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Never",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OC: oral contraceptives.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kaunitz, AM. Choosing to menstruate - or not. Contemporary OB/GYN 2001; 46:73. Copyright &copy; 2001 Medical Economics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31291=[""].join("\n");
var outline_f30_35_31291=null;
var title_f30_35_31292="Epiglottitis Rx regimens";
var content_f30_35_31292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous antimicrobial treatment regimens for epiglottitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pediatric dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adult dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Two-drug regimens",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ceftriaxone",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        50 to 100 mg/kg per day once daily or in two divided doses",
"       </p>",
"       <p>",
"        Maximum daily dose 2 g",
"       </p>",
"      </td>",
"      <td>",
"       2 g every 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cefotaxime",
"      </td>",
"      <td>",
"       <p>",
"        150 to 200 mg/kg per day in four divided doses",
"       </p>",
"       <p>",
"        Maximum daily dose 10 g",
"       </p>",
"      </td>",
"      <td>",
"       2 g every 4 to 8 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       <span class=\"red\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Vancomycin*",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        40 to 60 mg/kg per day in three to four divided doses",
"       </p>",
"       <p>",
"        Maximum daily dose 2 g",
"       </p>",
"      </td>",
"      <td>",
"       1 g every 12 hours (or 15 mg/kg every 12 hours if weight-based dosing is preferred)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Clindamycin",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        30 to 40 mg/kg per day in three divided doses",
"       </p>",
"       <p>",
"        Maximum daily dose 2.7 g",
"       </p>",
"      </td>",
"      <td>",
"       600 to 900 mg every 8 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Oxacillin&bull;",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        150 to 200 mg/kg per day in four divided doses",
"       </p>",
"       <p>",
"        Maximum daily dose 12 g",
"       </p>",
"      </td>",
"      <td>",
"       1 to 2 g every 4 to 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Nafcillin&bull;",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        150 to 200 mg/kg per day in four divided doses",
"       </p>",
"       <p>",
"        Maximum daily dose 12 g",
"       </p>",
"      </td>",
"      <td>",
"       2 g every 4 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cefazolin&bull;",
"      </td>",
"      <td>",
"       <p>",
"        75 to 100 mg/kg per day in three divided doses",
"       </p>",
"       <p>",
"        Maximum daily dose 6 g",
"       </p>",
"      </td>",
"      <td>",
"       1 to 2 g every 6 hours",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Vancomycin is indicated in patients with moderate to severe sepsis, patients who may have concomitant meningitis, and patients from areas with an increased prevalence of clindamycin-resistant and/or methicillin-resistant Staphylococcal aureus isolates.",
"     <br>",
"      &bull; Oxacillin, nafcillin, and cefazolin should only be used as part of combination therapy in patients for whom methicillin-resistant S. aureus is not a consideration.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31292=[""].join("\n");
var outline_f30_35_31292=null;
var title_f30_35_31293="Noninfectious causes generalized lymphadenopathy in children";
var content_f30_35_31293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Noninfectious causes of generalized lymphadenopathy in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neoplastic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected clinical features that may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hodgkin lymphoma",
"       </td>",
"       <td>",
"        Usually manifests as cervical lymphadenopathy; adenopathy may be unilateral; respiratory distress can occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-Hodgkin lymphoma",
"       </td>",
"       <td>",
"        Rapidly enlarging diffuse adenopathy, abdominal pain, vomiting; adenopathy is usually bilateral; respiratory distress can occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Metastatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute lymphocytic or myelogenous leukemia",
"       </td>",
"       <td>",
"        Ill appearance, bleeding, hepatosplenomegaly, anemia, thrombocytopenia; occipital nodes often prominent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroblastoma",
"       </td>",
"       <td>",
"        Abdominal mass; opsoclonus-myoclonus, proptosis, periorbital echymoses, nasal obstruction, Horner syndrome, subcutaneous nodules, secretory diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhabdomyosarcoma",
"       </td>",
"       <td>",
"        Proptosis; nasal, aural, or sinus obstruction; hematuria; urinary obstruction; constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Immunologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kawasaki disease",
"       </td>",
"       <td>",
"        Conjunctivitis, peeling skin on hands, diffuse rash, coronary artery dilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasculitis syndromes (systemic lupus erythematosus, rheumatoid arthritis)",
"       </td>",
"       <td>",
"        Patients may have generalized adenopathy during the acute phase of illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum sickness",
"       </td>",
"       <td>",
"        Rash, splenomegaly, myalgia, arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autoimmune hemolytic anemia",
"       </td>",
"       <td>",
"        Lymphadenopathy coincides with hemolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic granulomatous disease",
"       </td>",
"       <td>",
"        Recurrent infection, skin abscesses, suppurative adenitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gaucher disease",
"       </td>",
"       <td>",
"        Hepatosplenomegaly, anemia, thrombocytopenia, osteopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Niemann-Pick disease",
"       </td>",
"       <td>",
"        Hepatosplenomegaly, loss of neurologic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenytoin, phenobarbitol, carbamazepinem, isoniazid, aspirin, barbiturates, penicillin, tetracycline, iodides, sulfonamides, allopurinol, and phenylbutazone",
"       </td>",
"       <td>",
"        Severe maculopapular rash, fever, hepatosplenomegaly, jaundice, anemia, leukopenia, and plasmacytosis occurring during or after the lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        Multisystem granulomatous disease; generalized adenopathy with prominent cervical involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemophagocytic lymphohistiocytosis",
"       </td>",
"       <td>",
"        Fever, hepatosplenomegaly, neurologic symptoms, rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Castleman disease",
"       </td>",
"       <td>",
"        Fever, hepatosplenomegaly, polyclonal hypergammaglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Langerhans cell histiocytosis",
"       </td>",
"       <td>",
"        Rash (brown to purplish papules), mucosal lesions, lytic bone lesions, proptosis, diabetes insipidus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kikuchi-Fujimoto disease",
"       </td>",
"       <td>",
"        Cervical and supraclavicular adenopathy, fever, fatigue, weight loss, anemia, and leukopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy)",
"       </td>",
"       <td>",
"        Chronic bilateral cervical adenopathy is characteristic; other nodal groups are involved in most cases; fever, anemia, leukocytosis, elevated ESR, and hypergammaglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperthyroidism",
"       </td>",
"       <td>",
"        Tachycardia, hypertension, diaphoresis, weight loss, goiter, hyperreflexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papular acrodermatitis (Gianotti-Crosti syndrome)",
"       </td>",
"       <td>",
"        Rash on face, buttocks, limbs, palms, and soles; hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Progressive transformation of germinal centers",
"       </td>",
"       <td>",
"        Found in 10 percent of nodes with reactive hyperplasia; sometimes associated with prior diagnosis of Hodgkin lymphoma and rarely before the diagnosis of Hodgkin lymphoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Malley R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.421.",
"       </li>",
"       <li>",
"        Scagni P, Peisino MG, Bianchi M, et al. Kikuchi-Fujimoto disease is a rare cause of lymphadenopathy and fever of unknown origin in children. J Pediatr Hematol Oncol 2005; 27:337.",
"       </li>",
"       <li>",
"        Osborne BM, Butler JJ, Gresik MV. Progressive transformation of germainal centers: Comparison of 23 pediatric patients to the adult population. Modern Pathology 1992; 5:135.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31293=[""].join("\n");
var outline_f30_35_31293=null;
var title_f30_35_31294="Eisenmenger high hct management";
var content_f30_35_31294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management of erythrocytosis in Eisenmenger syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 354px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Volume depletion from pure water loss must be associated with hypernatremia.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Vongpatanasin, W, Brickner, E, Hillis, LD, et al, Ann Intern Med 1998; 128:749.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31294=[""].join("\n");
var outline_f30_35_31294=null;
var title_f30_35_31295="Gastric bezoar after gastrectomy UGI";
var content_f30_35_31295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric bezoar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An upper GI series in a patient status post Billroth 2 gastrectomy and vagotomy shows a large bezoar in the distended stomach. The patient presented with gastric outlet obstruction which arose from a stricture at the gastrojejunal anastomosis (arrow) and from vagotomy-induced hypoperistalsis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_35_31295=[""].join("\n");
var outline_f30_35_31295=null;
